Pca3, pca3 genes, and methods of use

ABSTRACT

The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional application of recently allowed U.S.application Ser. No. 11/260,282 which itself is a divisional of U.S.patent application Ser. No. 09/402,713, now U.S. Pat. No. 7,008,765 andwhich claims priority on international Application NumberPCT/CA98/000346 filed Apr. 9, 1998, which itself claims priority on U.S.provisional application Ser. No. 60/041,836 filed Apr. 10, 1997. Thepatent applications identified above are incorporated here by referencein their entirety to provide continuity of disclosure.

STATEMENT REGARDING FEDERALLY-SPONSORED RESEARCH AND DEVELOPMENT

Statement under MPEP 310. The U.S. government has a paid-up license inthis invention and the right in limited circumstances to require thepatent owner to license others on reasonable terms as provided for bythe terms of Grant No. CA 58236 awarded by the U.S. Department of Healthand Human Services National Institutes of Health.

Part of the work performed during development of this invention utilizedU.S. Government funds. The U.S. Government has certain rights in thisinvention.

FIELD OF THE INVENTION

The present invention relates, in general, to a prostate cancer antigen,PCA3. In particular, the present invention relates to nucleic acidmolecules coding for the PCA3 protein; purified PCA3 proteins andpolypeptides; recombinant nucleic acid molecules; cells containing therecombinant nucleic acid molecules; antibodies having binding affinityspecifically to PCA3 proteins and polypeptides; hybridomas containingthe antibodies; nucleic acid probes for the detection of nucleic acidsencoding PCA3 proteins; a method of detecting nucleic acids encodingPCA3 proteins or polypeptides in a sample; kits containing nucleic acidprobes or antibodies; bioassays using the nucleic acid sequence, proteinor antibodies of this invention to diagnose, assess, or prognose amammal afflicted with prostate cancer; therapeutic uses; and methods ofpreventing prostate cancer in an animal.

SEQUENCE LISTING

This application contains a Sequence Listing in computer readable formentitled “Sequence Listing”, created Oct. 23, 2009, having a size of14.4 Ko. The computer readable form is incorporated herein by reference.

BACKGROUND OF THE INVENTION

Prostate cancer is the most commonly diagnosed malignancy and the secondleading cause of cancer-related deaths in the western male population.When this carcinoma has locally or distantly spread, no curative therapycan be offered. Therefore, efforts to control the disease (i.e., todecrease prostate cancer mortality) have focused on increasing detectionof the cancer while it is still locally confined and potentiallycurable. Studies aimed at the early detection of prostate cancer havedemonstrated an appreciable increase in the detection of organ-confinedpotentially curable prostate cancers. However, it has not yet beendemonstrated that the increased detection rate will decrease theprostate cancer-specific mortality rates. On the other hand, there isalso no evidence that early diagnosis will decrease the mortality rates.Both in the United States and in Europe, discussions on the efficacy andacceptability of screening programs, the issue of overdiagnosis andovertreatment and the chances that early treatment will lead to reducedprostate cancer morbidity and mortality, are still ongoing and makeearly detection of prostate cancer a controversial issue (Schröder,Urology 46: 6270 (1995)).

Measurements of serum concentrations of prostatic marker enzymes haverecognized value in the clinical detection, diagnosis and management ofprostate cancer. The two most widely used prostatic marker enzymes areprostatic acid phosphatase (PAP) and prostate-specific antigen (PSA).Normally, both enzymes are secreted from the prostatic epithelial cellsinto the seminal fluid, but in patients with prostatic disease they leakinto the circulation, where they can be detected by means ofimmunological assays (Armbruster, Clin. Che. 39: 181-95 (1993)).

Prostatic acid phosphatase, one of the earliest serum markers forprostate, has an as yet undetermined function and is one of the mostpredominant protein components in human prostatic secretions. The use ofPAP as a marker for prostatic tumors is complicated by the reportedstructural similarities between the prostate-specific acid phosphataseand the lysosomal acid phosphatase occurring in all tissues.Furthermore, there is a tendency towards lower PAP mRNA and proteinlevels in prostate cancer in comparison with benign prostatichyperplasia (BPH). In recent years, PAP measurements were superseded byserum PSA measurements in the clinical management of prostate cancer.

Prostate-specific antigen was identified by several groups in the 1970'sas a prostate-specific protein from the seminal fluid. In 1979, it waspurified as an antigen from prostate cancer tissue. Further researchshowed that PSA is produced exclusively by the columnar epithelial cellsof the prostate and periuretural glands. Normal prostate epithelium andbenign hyperplastic tissue actually produce more PSA mRNA and proteinthan does prostate cancer tissue. Furthermore, it was shown that loss ofdifferentiation of prostatic carcinomas is associated with a decrease inthe level of intraprostatic PSA.

Abnormalities in prostate architecture occurring as a result ofprostatic disease lead to an increased leakage of PSA (and PAP) into theserum and make serum PSA measurements a marker for prostate cancer.Despite the fact that early studies have indicated that diagnostic PSAtesting would be hampered by the fact that it lacked specificity indifferentiating between BPH and prostate cancer, PSA testing wasintroduced in 1986 and revolutionized the management of patients withprostate cancer. Increased knowledge on the organ specificity of PSA andthe relationship of elevated serum PSA levels to prostate disease aswell as improvement of biopsy techniques and histological evaluation,led to a appreciation of the clinical value of PSA testing, a utilitynot yet achieved by any other (prostate) tumor marker. Cloning of thegene that encodes PSA revealed that it is a member of the humankallikrein gene family and resulted in the development of new approachesto the use of PSA as a marker: the very sensitive reverse transcriptaskepolymerase chain reaction (RT-PCR) method is used to detect extremelysmall numbers of malignant prostate cells in blood samples from prostatecancer patients and might provide a sensitive tool to identify patientswith micrometastatic disease (Moreno et al., Cancer Res. 52: 6110-12(1992); and Katz et al., Urology 43: 765-75 (1994)).

Prostate-specific membrane antigen (PSM) was originally identified usingan antibody developed by immunizing mice with the membrane fraction ofLNCaP human prostatic adenocarcinoma cells. Like PAP and PSA, PSM can bedetected in normal prostate, BPH and prostate cancer and is absent frommost other tissues. Also for PSM, RT-PCR studies have been developed todetect circulating prostate cancer cells, however, furtherinvestigations are required to establish the usefulness of PSM as markerfor prostatic cancer.

In summary, PSA is currently recognized as the premier marker forprostatic cancer, being useful for screening selected populations ofpatients with symptoms indicative of prostate cancer and for monitoringpatients after therapy, especially after surgical prostatectomy(measurable levels of PSA indicate residual disease or metastasis andincreasing PSA concentrations indicate recurrent disease). Thesignificant weaknesses of PSA as a tumor marker are that (1) PSA is notable to always distinguish prostate cancer from BPH; and (2) that itsexpression decreases with loss of differentiation of carcinomas.

In view of the fact that advanced prostate cancer remains a lifethreatening disease reaching a very significant proportion of the malepopulation, there remains a need for the development of new treatmentand diagnostic modalities for (late stage) prostate cancer.

The present invention seeks to meet these and other needs.

The present description refers to a number of documents, the contents ofwhich are herein incorporated in their entirety by reference.

SUMMARY OF THE INVENTION

The invention provides, in general, isolated nucleic acid moleculescoding for PCA3 or fragments thereof.

The invention further provides purified polypeptides encoding PCA3 or anepitope binding portion thereof.

The invention also provides nucleic acids for the specific detection ofthe presence of nucleic acids encoding PCA3 proteins or polypeptides ina sample.

The invention further provides a method of detecting nucleic acidencoding PCA3 in a sample.

The invention also provides a kit for detecting the presence of nucleicacid encoding PCA3 in a sample.

The invention further provides a recombinant nucleic acid moleculecomprising, 5′ to 3′, a promoter effective to initiate transcription ina host cell and the above-described isolated nucleic acid molecule.

The invention also provides a recombinant nucleic acid moleculecomprising a vector and the above-described isolated nucleic acidmolecule.

The invention further provides an antisense PCA3 nucleic acid molecule.

The invention also provides a cell that contains the above-describedrecombinant nucleic acid molecule.

The invention further provides a non-human organism that contains theabove-described recombinant nucleic acid molecule.

The invention also provides an antibody having binding affinityspecifically to PCA3 or an epitope-bearing portion thereof.

The invention further provides a method of detecting PCA3 in a sample.

The invention also provides a method of measuring the amount of PCA3 ina sample.

The invention in addition provides immunogenic reagents to induceprotection against PCA3-expressing prostate cancer cells. Preferably,such immunogenic reagents are polypeptides encoding PCA3, an antigenicportion thereof, fusion proteins encoding PCA3 or fusion proteinencoding antigenic portions of PCA3. In such an embodiment, theseimmunogenic reagents would function as vaccine agents.

The invention further provides a method of detecting antibodies havingbinding affinity specifically to PCA3.

The invention further provides a diagnostic kit comprising a firstcontainer means containing the above-described antibody, and a secondcontainer means containing a conjugate comprising a binding partner ofthe monoclonal antibody and a label.

The invention also provides a hybridoma which produces theabove-described monoclonal antibody.

The invention further provides diagnostic methods for human disease, inparticular, prostate cancer. Preferably, a method of diagnosing thepresence or predisposition to develop prostate cancer in a patient isprovided herein.

The invention also provides methods for therapeutic uses involving allor part of (1) a nucleic acid sequence encoding PCA3, (2) antisense PCA3nucleic acid molecules, (2) PCA3 protein, or (4) PCA3 antibodies.

Further objects and advantages of the present invention will be clearfrom the description that follows.

DEFINITIONS

In the description that follows, a number of terms used in recombinantDNA (rDNA) technology are extensively utilized. In order to provide aclear and consistent understanding of the specification and claims,including the scope to be given such terms, the following definitionsare provided.

Isolated Nucleic Acid Molecule. An “isolated nucleic acid molecule”, asis generally understood and used herein, refers to a polymer ofnucleotides, and includes but should not be limited to DNA and RNA. The“isolated” nucleic acid molecule is purified from its natural in vivostate.

Recombinant DNA. Any DNA molecule formed by joining DNA segments fromdifferent sources and produced using recombinant DNA technology (aka.molecular genetic engineering).

DNA Segment. A DNA segment, as is generally understood and used herein,refers to a molecule comprising a linear stretch of nucleotides whereinthe nucleotides are present in a sequence that can encode, through thegenetic code, a molecule comprising a linear sequence of amino acidresidues that is referred to as a protein, a protein fragment or apolypeptide.

Gene. A DNA sequence related to a single polypeptide chain or protein,and as used herein includes the 5′ and 3′ untranslated ends. Thepolypeptide can be encoded by a full-length sequence or any portion ofthe coding sequence, so long as the functional activity of the proteinis retained.

Complementary DNA (cDNA). Recombinant nucleic acid molecules synthesizedby reverse transcription of messenger RNA (“mRNA”).

Structural Gene. A DNA sequence that is transcribed into mRNA that isthen translated into a sequence of amino acids characteristic of aspecific polypeptide.

Restriction Endonuclease. A restriction endonuclease (also restrictionenzyme) is an enzyme that has the capacity to recognize a specific basesequence (usually 4, 5, or 6 base pairs in length) in a DNA molecule,and to cleave the DNA molecule at every place where this sequenceappears. For example, EcoRI recognizes the double-stranded palindromicbase sequence 5′-GAATTC-3′/3′-CTTAAG-5′.

Restriction Fragment. The DNA molecules produced by digestion with arestriction endonuclease are referred to as restriction fragments. Anygiven genome can be digested by a particular restriction endonucleaseinto a discrete set of restriction fragments.

Agarose Gel Electrophoresis. To detect a polymorphism in the length ofrestriction fragments, an analytical method for fractionatingdouble-stranded DNA molecules on the basis of size is required. The mostcommonly used technique (though not the only one) for achieving such afractionation is agarose gel electrophoresis. The principle of thismethod is that DNA molecules migrate through the gel as though it were asieve that retards the movement of the largest molecules to the greatestextent and the movement of the smallest molecules to the least extent.Note that the smaller the DNA fragment, the greater the mobility underelectrophoresis in the agarose gel.

The DNA fragments fractionated by agarose gel electrophoresis can bevisualized directly by a staining procedure if the number of fragmentsincluded in the pattern is small. The DNA fragments of genomes can bevisualized successfully. However, most genomes, including the humangenome, contain far too many DNA sequences to produce a simple patternof restriction fragments. For example, the human genome is digested intoapproximately 1,000,000 different DNA fragments by EcoRI. In order tovisualize a small subset of these fragments, a methodology referred toas the Southern hybridization procedure can be applied.

Southern Transfer Procedure. The purpose of the Southern transferprocedure (also referred to as blotting) is to physically transfer DNAfractionated by agarose gel electrophoresis onto a nitrocellulose filterpaper or another appropriate surface or method, while retaining therelative positions of DNA fragments resulting from the fractionationprocedure. The methodology used to accomplish the transfer from agarosegel to nitrocellulose involves drawing the DNA from the gel into thenitrocellulose paper by capillary action.

Nucleic Acid Hybridization. Nucleic acid hybridization depends on theprinciple that two single-stranded nucleic acid molecules that havecomplementary base sequences will reform the thermodynamically favoreddouble-stranded structure if they are mixed under the proper conditions.The double-stranded structure will be formed between two complementarysingle-stranded nucleic acids even if one is immobilized on anitrocellulose filter. In the Southern hybridization procedure, thelatter situation occurs. As noted previously, the DNA of the individualto be tested is digested with a restriction endonuclease, fractionatedby agarose gel electrophoresis, converted to the single-stranded form,and transferred to nitrocellulose paper, making it available forreannealing to the hybridization probe. Examples of hybridizationconditions can be found in Ausubel, F. M. et al., Current protocols inMolecular Biology, John Wily & Sons, Inc., New York, N.Y. (1989). Anitrocellulose filter is incubated overnight at 68° C. with labeledprobe in a solution containing 50% formamide, high salt (either5×SSC[20×: 3M NaCl/0.3M trisodium citrate] or 5×SSPE [20×: 3.6MNaCl/0.2M NaH₂PO₄/0.02M EDTA, pH 7.7]), 5×Denhardt's solution, 1% SDS,and 100 μg/ml denatured salmon sperm DNA. This is followed by severalwashes in 0.2×SSC/0.1% SDS at a temperature selected based on thedesired stringency: room temperature (low stringency), 42° C. (moderatestringency) or 68° C. (high stringency). The temperature selected isdetermined based on the melting temperature (Tm) of the DNA hybrid.

Hybridization Probe. To visualize a particular DNA sequence in theSouthern hybridization procedure, a labeled DNA molecule orhybridization probe is reacted to the fractionated DNA bound to thenitrocellulose filter. The areas on the filter that carry DNA sequencescomplementary to the labeled DNA probe become labeled themselves as aconsequence of the reannealing reaction. The areas of the filter thatexhibit such labeling are visualized. The hybridization probe isgenerally produced by molecular cloning of a specific DNA sequence.

Oligonucleotide or Oligomer. A molecule comprised of two or moredeoxyribonucleotides or ribonucleotides, preferably more than three. Itsexact size will depend on many factors, which in turn depend on theultimate function or use of the oligonucleotide. An oligonucleotide canbe derived synthetically or by cloning.

Sequence Amplification. A method for generating large amounts of atarget sequence. In general, one or more amplification primers areannealed to a nucleic acid sequence. Using appropriate enzymes,sequences found adjacent to, or in between the primers are amplified.

Amplification Primer. An oligonucleotide which is capable of annealingadjacent to a target sequence and serving as an initiation point for DNAsynthesis when placed under conditions in which synthesis of a primerextension product which is complementary to a nucleic acid strand isinitiated.

Antisense nucleic acid molecule. An “antisense nucleic acid molecule”refers herein to a molecule capable of forming a stable duplex ortriplex with a portion of its targeted nucleic acid sequence (DNA orRNA). The use of antisense nucleic acid molecules and the design andmodification of such molecules is well known in the art as described forexample in WO 96/32966, WO 96/11266, WO 94/15646, WO 93/08845, and U.S.Pat. No. 5,593,974. Antisense nucleic acid molecules according to thepresent invention can be derived from the nucleic acid sequences of thepresent invention and modified in accordance to well known methods. Forexample, some antisense molecules can be designed to be more resistantto degradation, to increase their affinity to their targeted sequence,to affect their transport to chosen cell types or cell compartments,and/or to enhance their lipid solubility by using nucleotide analogsand/or substituting chosen chemical fragments thereof, as commonly knownin the art.

Vector. A plasmid or phage DNA or other DNA sequence into which DNA canbe inserted to be cloned. The vector can replicate autonomously in ahost cell, and can be further characterized by one or a small number ofendonuclease recognition sites at which such DNA sequences can be cut ina determinable fashion and into which DNA can be inserted. The vectorcan further contain a marker suitable for use in the identification ofcells transformed with the vector. Markers, for example, aretetracycline resistance or ampicillin resistance. The words “cloningvehicle” are sometimes used for “vector.”

Expression. Expression is the process by which a structural geneproduces a polypeptide. It involves transcription of the gene into mRNA,and the translation of such mRNA into polypeptide(s).

Expression Vector. A vector or vehicle similar to a cloning vector butwhich is capable of expressing a gene which has been cloned into it,after transformation into a host. The cloned gene is usually placedunder the control of (i.e., operably linked to) certain controlsequences such as promoter sequences.

Expression control sequences will vary depending on whether the vectoris designed to express the operably linked gene in a prokaryotic oreukaryotic host and can additionally contain transcriptional elementssuch as enhancer elements, termination sequences, tissue-specificityelements, and/or translational initiation and termination sites.

Functional Derivative. A “functional derivative” of a sequence, eitherprotein or nucleic acid, is a molecule that possesses a biologicalactivity (either functional or structural) that is substantially similarto a biological activity of the protein or nucleic acid sequence. Afunctional derivative of a protein can contain post-translationalmodifications such as covalently linked carbohydrate, depending on thenecessity of such modifications for the performance of a specificfunction. The term “functional derivative” is intended to include the“fragments,” “segments,” “variants,” “analogs,” or “chemicalderivatives” of a molecule.

As used herein, a molecule is said to be a “chemical derivative” ofanother molecule when it contains additional chemical moieties notnormally a part of the molecule. Such moieties can improve themolecule's solubility, absorption, biological half life, and the like.The moieties can alternatively decrease the toxicity of the molecule,eliminate or attenuate any undesirable side effect of the molecule, andthe like. Moieties capable of mediating such effects are disclosed inRemington's Pharmaceutical Sciences (1980). Procedures for coupling suchmoieties to a molecule are well known in the art.

Variant. A “variant” of a protein or nucleic acid is meant to refer to amolecule substantially similar in structure and biological activity toeither the protein or nucleic acid. Thus, provided that two moleculespossess a common activity and can substitute for each other, they areconsidered variants as that term is used herein even if the compositionor secondary, tertiary, or quaternary structure of one of the moleculesis not identical to that found in the other, or if the amino acid ornucleotide sequence is not identical.

Allele. An “allele” is an alternative form of a gene occupying a givenlocus on the chromosome.

Mutation. A “mutation” is any detectable change in the genetic materialwhich can be transmitted to daughter cells and possibly even tosucceeding generations giving rise to mutant cells or mutantindividuals. If the descendants of a mutant cell give rise only tosomatic cells in multicellular organisms, a mutant spot or area of cellsarises. Mutations in the germ line of sexually reproducing organisms canbe transmitted by the gametes to the next generation resulting in anindividual with the new mutant condition in both its somatic and germcells. A mutation can be any (or a combination of) detectable, unnaturalchange affecting the chemical or physical constitution, mutability,replication, phenotypic function, or recombination of one or moredeoxyribonucleotides; nucleotides can be added, deleted, substitutedfor, inverted, or transposed to new positions with and withoutinversion. Mutations can occur spontaneously and can be inducedexperimentally by application of mutagens. A mutant variation of anucleic acid molecule results from a mutation. A mutant polypeptide canresult from a mutant nucleic acid molecule.

Species. A “species” is a group of actually or potentially interbreedingnatural populations. A species variation within a nucleic acid moleculeor protein is a change in the nucleic acid or amino acid sequence thatoccurs among species and can be determined by DNA sequencing of themolecule in question.

Polyacrylamide Gel Electrophoresis (PAGE). The most commonly usedtechnique (though not the only one) for achieving a fractionation ofpolypeptides on the basis of size is polyacrylamide gel electrophoresis.The principle of this method is that polypeptide molecules migratethrough the gel as though it were a sieve that retards the movement ofthe largest molecules to the greatest extent and the movement of thesmallest molecules to the least extent. Note that the smaller thepolypeptide fragment, the greater the mobility under electrophoresis inthe polyacrylamide gel. Both before and during electrophoresis, thepolypeptides typically are continuously exposed to the detergent sodiumdodecyl sulfate (SDS), under which conditions the polypeptides aredenatured. Native gels are run in the absence of SDS. The polypeptidesfractionated by polyacrylamide gel electrophoresis can be visualizeddirectly by a staining procedure if the number of polypeptide componentsis small.

Western Transfer Procedure. The purpose of the Western transferprocedure (also referred to as blotting) is to physically transferpolypeptides fractionated by polyacrylamide gel electrophoresis onto anitrocellulose filter paper or another appropriate surface or method,while retaining the relative positions of polypeptides resulting fromthe fractionation procedure. The blot is then probed with an antibodythat specifically binds to the polypeptide of interest.

Purified. A “purified” protein or nucleic acid is a protein or nucleicacid that has been separated from a cellular component. “Purified”proteins or nucleic acids have been purified to a level of purity notfound in nature.

Substantially Pure. A “substantially pure” protein or nucleic acid is aprotein or nucleic acid preparation that is lacking in all othercellular components.

BRIEF DESCRIPTION OF THE DRAWINGS

Having thus generally described the invention, reference will now bemade to the accompanying drawings, showing by way of illustration apreferred embodiment thereof, and in which:

FIG. 1 shows the genomic structure of the PCA3 gene.

FIG. 2A-J, (A) a PCA3 cDNA structure; (B)-(J) a PCA3 nucleotide andamino acid cDNA sequence (SEQ ID NOs:1 and 2).

FIG. 3 is a schematic representation comparing cDNA clones pMB9 andλDD3.6.

FIG. 4 shows the location of a transcription start site (TSS) of PCA3.The transcription start site was determined by primer extension (PE),S1-nuclease mapping (S1), and 5′ Rapid Amplification of cDNA Ends (RACE)assays. The sequence in FIG. 4 (SEQ ID NO: 9) is as set forth betweennucleotides 1 and 120 of SEQ ID NO:6 with a “g” nucleotide and a “gt”dinucleotide at the 5′ and 3′ ends respectively.

FIG. 5A-F (A) a PCA3 cDNA structure; (B)-(F) a PCA3 nucleotide and aminoacid cDNA sequence (SEQ ID NOs:6 and 7); putative poly-adenylationsignals are underlined.

Other objects, advantages and features of the present invention willbecome more apparent upon reading of the following non-restrictivedescription of preferred embodiments with reference to the accompanyingdrawings which are exemplary and should not be interpreted as limitingthe scope of the present invention.

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

For purposes of clarity of disclosure, and not by way of limitation, thedetailed description of the invention is divided into the followingsubsections:

I. Isolated Nucleic Acid Molecules Coding for PCA3 Polypeptides.

II. Purified PCA3 Polypeptides.

III. A Nucleic Acid for the Specific Detection of PCA3 Nucleic Acid.

IV. A Method of Detecting the Presence of PCA3 Nucleic Acid in a Sample.

V. A Kit for Detecting the Presence of PCA3 Nucleic Acid in a Sample.

VI. DNA Constructs Comprising a PCA3 Nucleic Acid Molecule and CellsContaining These Constructs.

VII. An Antibody Having Binding Affinity to a PCA3 Polypeptide and aHybridoma Containing the Antibody.

VIII. A Method of Detecting a PCA3 Polypeptide or Antibody in a Sample.

IX. A Diagnostic Kit Comprising a PCA3 Protein or Antibody.

X. Diagnostic Screening.

XI. Therapeutic Treatments.

XII. Transgenic PCA3 Non-human Animals.

I. Isolated Nucleic Acid Molecules Coding for PCA3 Polypeptides

In one embodiment, the present invention relates to isolated (purified)PCA3 nucleic acid molecules. Preferably, the PCA3 nucleic acid moleculecomprises a polynucleotide sequence at least 90% identical (morepreferably, 95%, 96%, 97%, 98%, 99% or 100% identical) to a sequenceselected from the group consisting of:

(a) a nucleotide sequence encoding a PCA3 polypeptide comprising thecomplete amino acid sequence in SEQ ID NO:2 or SEQ ID NO:7;

(b) a nucleotide sequence encoding a PCA3 polypeptide comprising thecomplete amino acid sequence encoded by the polynucleotide clonecontained in the deposit at the Centraal voor Schimmelcultures asaccession number CBS 682.97;

(c) a nucleotide sequence encoding a PCA3 polypeptide comprising thecomplete amino acid sequence encoded by the polynucleotide clonecontained in the deposit at the Centraal voor Schimmelcultures asaccession number CBS 100521; and

(d) a nucleotide sequence complementary to any of the nucleotidesequences in (a), (b), or (c).

pMB9 is a PCA3 cDNA clone which contains exons 1, 2, 3, 4a and 4b of thePCA3 gene. pMB9 was deposited at the Phabagen Collection, University ofUtrecht, Padualaan 8, 3584 CH Utrecht (which is a division of theCentraalbureau voor Schimmelcultures, Oosterstratt1, Postbus 273, 3740AG Baarn) under the regulations of the Budapest Treaty on Apr. 10, 1997as accession number CBS 682.97.

λDD3.6 is a PCA3 cDNA clone which contains exons 3, 4a, 4b, 4c, and 4d.λDD3.6 was deposited at the Phabagen Collection, University of Utrecht,Padualaan 8, 3584 CH Utrecht (which is a division of the Centraalbureauvoor Schimmelcultures, Oosterstratt1, Postbus 273, 3740 AG Baarn) underthe regulations of the Budapest Treaty on Mar. 27, 1998 as accessionnumber CBS 100521.

In one preferred embodiment, the isolated nucleic acid moleculecomprises a PCA3 nucleotide sequence with greater than 90% identity orsimilarity to the nucleotide sequence present in SEQ ID NO:1 (preferablygreater than 95%, 96%, 97%, 98%, 99% or 100%). In another preferredembodiment, the isolated nucleic acid molecule comprises the PCA3 codingsequence present in SEQ ID NO:1. In another embodiment, the isolatednucleic acid molecule encodes the PCA3 amino acid sequence present inSEQ ID NO:2 or SEQ ID NO:7. In yet another embodiment, the isolatednucleic acid molecule comprises a PCA3 nucleotide sequence with greaterthan 90% identity or similarity to the nucleotide sequence present inSEQ ID NO:6 (preferably greater than 95%, 96%, 97%, 98%, 99% or 100%).In another preferred embodiment, the isolated nucleic acid moleculecomprises the PCA3 coding sequence present in SEQ ID NO:6.

Also included within the scope of this invention are isolated nucleicacids comprising cDNA splice variants of PCA3 or polynucleotidesequences which are at least 90% identical thereto, preferably at least95% identical thereto. In view of the fact that virtually allcombinations of exons are possible, non-limiting examples of such splicevariants include isolated PCA3 nucleic acids comprising exons 1, 2, 3,4a and 4b (SEQ ID NO:1); exons 1, 3, 4a, 4b, and 4c (SEQ ID NO:3 andregion 4c which is contiguous to region 4b, see FIG. 1); exons 1, 3, 4a,4b, 4c, and 4d (SEQ ID NO:3 and region 4c which is contiguous to region4b and region 4d which is contiguous to region 4c, see FIG. 1); exons 1,3, 4a, and 4b (SEQ ID NO:3); exons 1, 3, and 4a (SEQ ID NO:4); exons 1,2, 3, 4a, 4b, 4c, and 4d (SEQ ID NO:6) Preferably, the PCA3 nucleic acidmolecule comprises a polynucleotide sequence at least 90% identical(more preferably, 95%, 96%, 97%, 98%, 99% or 100% identical) to one ofthe above-described splice variants.

Also included within the scope of this invention are the functionalequivalents of the herein-described isolated nucleic acid molecules andderivatives thereof. For example, the nucleic acid sequences depicted inSEQ ID NO:1 or SEQ ID NO:6 can be altered by substitutions, additions ordeletions that provide for functionally equivalent molecules. Due to thedegeneracy of nucleotide coding sequences, other DNA sequences whichencode substantially the same amino acid sequence as depicted in SEQ IDNO:2 and SEQ ID NO:7 can be used in the practice of the presentinvention. These include but are not limited to nucleotide sequencescomprising all or portions of PCA3 nucleic acid depicted in SEQ ID NO:1,3, 4 or 6, which are altered by the substitution of different codonsthat encode a functionally equivalent amino acid residue within thesequence.

In addition, the nucleic acid sequence can comprise a nucleotidesequence which results from the addition, deletion or substitution of atleast one nucleotide to the 5′-end and/or the 3′-end of the nucleic acidformula shown in SEQ ID NO:1, 3, 4, or 6 or a derivative thereof. Anynucleotide or polynucleotide can be used in this regard, provided thatits addition, deletion or substitution does not substantially alter theamino acid sequence of SEQ ID NO:2, or SEQ ID NO:7 which is encoded bythe nucleotide sequence. Moreover, the nucleic acid molecule of thepresent invention can, as necessary, have restriction endonucleaserecognition sites added to its 5′-end and/or 3′-end. All variations ofthe nucleotide sequence of the PCA3 nucleotide coding sequence andfragments thereof permitted by the genetic code are, therefore, includedin this invention.

Further, it is possible to delete codons or to substitute one or morecodons by codons other than degenerate codons to produce a structurallymodified polypeptide, but one which has substantially the same utilityor activity of the polypeptide produced by the unmodified nucleic acidmolecule. As recognized in the art, the two polypeptides arefunctionally equivalent, as are the two nucleic acid molecules whichgive rise to their production, even though the differences between thenucleic acid molecules are not related to degeneracy of the geneticcode.

A. Isolation of Nucleic Acid

In one aspect of the present invention, isolated nucleic acid moleculescoding for polypeptides having amino acid sequences corresponding toPCA3 are provided. In particular, the nucleic acid molecule can beisolated from a biological sample containing PCA3 RNA or DNA.

The nucleic acid molecule can be isolated from a biological samplecontaining PCA3 RNA using the techniques of cDNA cloning and subtractivehybridization. The nucleic acid molecule can also be isolated from acDNA library using a homologous probe.

The nucleic acid molecule can be isolated from a biological samplecontaining genomic DNA or from a genomic library. Suitable biologicalsamples include, but are not limited to, whole organisms, organs,tissues, blood and cells. The method of obtaining the biological samplewill vary depending upon the nature of the sample.

One skilled in the art will realize that genomes can be subject toslight allelic variations between individuals. Therefore, the isolatednucleic acid molecule is also intended to include allelic variations, solong as the sequence is a functional derivative of the PCA3 codingsequence. When a PCA3 allele does not encode the identical sequence tothat found in SEQ ID NO:1 or 6, it can be isolated and identified asPCA3 using the same techniques used herein, and especially PCRtechniques to amplify the appropriate gene with primers based on thesequences disclosed herein.

One skilled in the art will realize that organisms other than humanswill also contain PCA3 genes (for example, eukaryotes; morespecifically, mammals, birds, fish, and plants; more specifically,gorillas, rhesus monkeys, and chimpanzees). The invention is intended toinclude, but not be limited to, PCA3 nucleic acid molecules isolatedfrom the above-described organisms.

B. Synthesis of Nucleic Acid

Isolated nucleic acid molecules of the present invention are also meantto include those chemically synthesized. For example, a nucleic acidmolecule with the nucleotide sequence which codes for the expressionproduct of a PCA3 gene can be designed and, if necessary, divided intoappropriate smaller fragments. Then an oligomer which corresponds to thenucleic acid molecule, or to each of the divided fragments, can besynthesized. Such synthetic oligonucleotides can be prepared, forexample, by the triester method of Matteucci et al., J. Am. Chem. Soc.103:3185-3191 (1981) or by using an automated DNA synthesizer.

An oligonucleotide can be derived synthetically or by cloning. Ifnecessary, the 5′-ends of the oligomers can be phosphorylated using T4polynucleotide kinase. Kinasing of single strands prior to annealing orfor labeling can be achieved using an excess of the enzyme. If kinasingis for the labeling of probe, the ATP can contain high specific activityradioisotopes. Then, the DNA oligomer can be subjected to annealing andligation with T4 ligase or the like.

II. Purified PCA3 Polypeptides

In another embodiment, the present invention relates to a purifiedpolypeptide (preferably, substantially pure) having an amino acidsequence corresponding to PCA3, or a functional derivative thereof. In apreferred embodiment, the polypeptide has the amino acid sequence setforth in SEQ ID NO:2 or 7 or mutant or species variation thereof, or atleast 80% identity or at least 90% similarity thereof (preferably, atleast 90%, 95%, 96%, 97%, 98%, or 99% identity or at least 95%, 96%,97%, 98%, or 99% similarity thereof), or at least 6 contiguous aminoacids thereof (preferably, at least 10, 15, 20, 25, or 50 contiguousamino acids thereof).

In a preferred embodiment, the invention relates to PCA3 epitopes. Theepitope of these polypeptides is an immunogenic or antigenic epitope. Animmunogenic epitope is that part of the protein which elicits anantibody response when the whole protein is the immunogen. An antigenicepitope is a fragment of the protein which can elicit an antibodyresponse. Methods of selecting antigenic epitope fragments are wellknown in the art. See, Sutcliffe et al., Science 219:660-666 (1983).Antigenic epitope-bearing peptides and polypeptides of the invention areuseful to raise an immune response that specifically recognizes thepolypeptides. Antigenic epitope-bearing peptides and polypeptides of theinvention comprise at least 7 amino acids (preferably, 9, 10, 12, 15 or20 amino acids) of the proteins of the invention. An example of aantigenic peptide is HTQEAQKEAQR (SEQ ID NO:5).

Amino acid sequence variants of PCA3 can be prepared by mutations in theDNA. Such variants include, for example, deletions from, or insertionsor substitutions of, residues within the amino acid sequence shown inSEQ ID NO:2 or 7. Any combination of deletion, insertion, andsubstitution can also be made to arrive at the final construct, providedthat the final construct possesses the desired activity.

While the site for introducing an amino acid sequence variation ispredetermined, the mutation per se need not be predetermined. Forexample, to optimize the performance of a mutation at a given site,random mutagenesis can be conducted at the target codon or region andthe expressed PCA3 variants screened for the optimal combination ofdesired activity. Techniques for making substitution mutations atpredetermined sites in DNA having a known sequence are well known, forexample, site-specific mutagenesis.

Preparation of a PCA3 variant in accordance herewith is preferablyachieved by site-specific mutagenesis of DNA that encodes an earlierprepared variant or a nonvariant version of the protein. Site-specificmutagenesis allows the production of PCA3 variants through the use ofspecific oligonucleotide sequences that encode the DNA sequence of thedesired mutation. In general, the technique of site-specific mutagenesisis well known in the art, as exemplified by publications such as Adelmanet al., DNA 2:183 (1983) and Ausubel et al. “Current Protocols inMolecular Biology”, J. Wiley & Sons, NY, N.Y., 1996.

Amino acid sequence deletions generally range from about 1 to 30residues, more preferably 1 to 10 residues, and typically arecontiguous.

Amino acid sequence insertions include amino and/or carboxyl-terminalfusions of from one residue to polypeptides of essentially unrestrictedlength, as well as intrasequence insertions of single or multiple aminoacid residues. Intrasequence insertions (i.e., insertions within thecomplete PCA3 sequence) can range generally from about 1 to 10 residues,more preferably 1 to 5.

The third group of variants are those in which at least one amino acidresidue in the PCA3 molecule, and preferably, only one, has been removedand a different residue inserted in its place. Such substitutionspreferably are made in accordance with the following Table 1 when it isdesired to modulate finely the characteristics of PCA3.

TABLE 1 Original Residue Exemplary Substitutions Ala gly; ser Arg lysAsn gln; his Asp glu Cys ser Gln asn Glu asp Gly ala; pro His asn; glnIle leu; val Leu ile; val Lys arg; gln; glu Met leu; tyr; ile Phe met;leu; tyr Ser thr Thr ser Trp tyr Tyr trp; phe Val ile; leu

Substantial changes in functional or immunological identity are made byselecting substitutions that are less conservative than those in Table1, i.e., selecting residues that differ more significantly in theireffect on maintaining (a) the structure of the polypeptide backbone inthe area of the substitution, for example, as a sheet or helicalconformation, (b) the charge or hydrophobicity of the molecule at thetarget site, or (c) the bulk of the side chain. The substitutions thatin general are expected are those in which (a) glycine and/or proline issubstituted by another amino acid or is deleted or inserted; (b) ahydrophilic residue, e.g., seryl or threonyl, is substituted for (or by)a hydrophobic residue, e.g., leucyl, isoleucyl, phenylalanyl, valyl, oralanyl; (c) a cysteine residue is substituted for (or by) any otherresidue; (d) a residue having an electropositive side chain, e.g.,lysyl, arginyl, or histidyl, is substituted for (or by) a residue havingan electronegative charge, e.g., glutamyl or aspartyl; or (e) a residuehaving a bulky side chain, e.g., phenylalanine, is substituted for (orby) one not having such a side chain, e.g., glycine.

Some deletions and insertions, and substitutions are not expected toproduce radical changes in the characteristics of PCA3. However, when itis difficult to predict the exact effect of the substitution, deletion,or insertion in advance of doing so, one skilled in the art willappreciate that the effect will be evaluated by routine screeningassays. For example, a variant typically is made by site-specificmutagenesis of the native PCA3 encoding-nucleic acid, expression of thevariant nucleic acid in recombinant cell culture, and, optionally,purification from the cell culture, for example, by immunoaffinityadsorption on a column (to absorb the variant by binding it to at leastone remaining immune epitope). The activity of the cell lysate orpurified PCA3 molecule variant is then screened in a suitable screeningassay for the desired characteristic. For example, a change in theimmunological character of the PCA3 molecule, such as affinity for agiven antibody, is measured by a competitive type immunoassay. Changesin immunomodulation activity are measured by the appropriate assay.Modifications of such protein properties as redox or thermal stability,hydrophobicity, susceptibility to proteolytic degradation or thetendency to aggregate with carriers or into multimers are assayed bymethods well known to the ordinarily skilled artisan.

A variety of methodologies known in the art can be utilized to obtainthe peptide of the present invention. In one embodiment, the peptide ispurified from tissues or cells which naturally produce the peptide.Alternatively, the above-described isolated nucleic acid fragments canbe used to express the PCA3 protein in any organism. The samples of thepresent invention include cells, protein extracts or membrane extractsof cells, or biological fluids. The sample will vary based on the assayformat, the detection method and the nature of the tissues, cells orextracts used as the sample.

Any organism can be used as a source for the peptide of the invention,as long as the source organism naturally contains such a peptide. Asused herein, “source organism” refers to the original organism fromwhich the amino acid sequence of the subunit is derived, regardless ofthe organism the subunit is expressed in and ultimately isolated from.

One skilled in the art can readily follow known methods for isolatingproteins in order to obtain the peptide free of natural contaminants.These include, but are not limited to: immunochromotography,size-exclusion chromatography, HPLC, ion-exchange chromatography, andimmuno-affinity chromatography.

In a preferred embodiment, the purification procedures compriseion-exchange chromatography and size exclusion chromatography. Any oneof a large number of ion-exchange resins known in the art can beemployed, including for example, monoQ, sepharose Q, macro-prepQ,AG1-X2, or HQ. Examples of suitable size exclusion resins include, butare not limited to, Superdex 200, Superose 12, and Sephycryl 200.Elution can be achieved with aqueous solutions of potassium chloride orsodium chloride at concentrations ranging from 0.01M to 2.0M.

III. A Nucleic Acid for the Specific Detection of PCA3 Nucleic Acid

In another embodiment, the present invention relates to a nucleic acidfor the specific detection of the presence of PCA3 nucleic acid in asample comprising the above-described nucleic acid molecules or at leasta fragment thereof which binds under stringent conditions to PCA3nucleic acid.

In one preferred embodiment, the present invention relates to anisolated nucleic acid consisting of 10 to 1000 nucleotides (preferably,10 to 500, 10 to 100, 10 to 50, 10 to 35, 20 to 1000, 20 to 500, 20 to100, 20 to 50, or 20 to 35) which hybridizes preferentially to RNA orDNA encoding PCA3 or to a PCA3 gene but not to RNA or DNA of which isnot related to PCA3, wherein said nucleic acid probe is or iscomplementary to a nucleotide sequence consisting of at least 10consecutive nucleotides (preferably, 15, 18, 20, 25, or 30) from thenucleic acid molecule comprising a polynucleotide sequence at least 90%identical to a sequence selected from the group consisting of:

(a) a nucleotide sequence encoding the PCA3 polypeptide comprising thecomplete amino acid sequence in SEQ ID NO:2 or 7;

(b) a nucleotide sequence encoding the PCA3 polypeptide comprising thecomplete amino acid sequence encoded by the polynucleotide clonecontained in the deposit at the Centraal voor Schimmelcultures asaccession number CBS 682.97, respectively;

(c) a nucleotide sequence encoding the PCA3 polypeptide comprising thecomplete amino acid sequence encoded by the polynucleotide clonecontained in the deposit at the Centraal voor Schimmelcultures asaccession number CBS 100521, respectively;

(d) a nucleotide sequence encoding the PCA3 gene comprising thenucleotide sequence in SEQ ID NO:1, 3, 4, or 6;

(e) a nucleotide sequence encoding an exon of the PCA3 gene comprisingnucleotides 1-98, 99-263, 264-446, 447-985 or 986-2037 as set forth inSEQ ID NO:1;

(f) a nucleotide sequence encoding an exon of the PCA3 gene comprisingnucleotides 1-120, 121-285, 286-468, 469-1007, 1008-2066, 2067-2622 or2623-3582 as set forth in SEQ ID NO:6;

(g) a nucleotide sequence complementary to any of the nucleotidesequences in (a), (b), (c), (d), (e) or (f); and

(h) a nucleotide sequence as previously described above.

Preferably, the nucleic acid does not specifically hybridize tonucleotides 511-985 of SEQ ID NO:1, to nucleotides 567-961 of SEQ IDNO:1, to nucleotides 533-1007 of SEQ ID NO:6, or to nucleotides 589-983of SEQ ID NO:6.

Complementary sequences are also known as antisense nucleic acids whenthey comprise sequences which are complementary to the coding strand.

Examples of specific nucleic acid probes which can be used in thepresent invention are set forth in Table 2, below.

TABLE 2 NUCLEIC ACID PROBES Size (no. of bases) Nucleotides Exon 1 981-98 of SEQ ID NO: 1 Exon 2 165 99-263 of SEQ ID NO: 1 Exon 3 183264-446 of SEQ ID NO: 1 Exon 4a 539 447-985 of SEQ ID NO: 1 Exon 4b 1052986-2037 of SEQ ID NO: 1 Probe 1 20 1-20 of SEQ ID NO: 1 Probe 2 30 1-30of SEQ ID NO: 1 Probe 3 40 1-40 of SEQ ID NO: 1 Probe 4 20 381-400 ofSEQ ID NO: 1 Probe 5 30 381-410 of SEQ ID NO: 1 Probe 6 20 401-420 ofSEQ ID NO: 1 Probe 7 30 401-430 of SEQ ID NO: 1 Probe 8 20 511-530 ofSEQ ID NO: 1 Probe 9 30 501-530 of SEQ ID NO: 1 Probe 10 20 77-98 of SEQID NO: 1 Probe 11 20 99-118 of SEQ ID NO: 1 Probe 12 20 244-263 of SEQID NO: 1 Probe 13 20 264-283 of SEQ ID NO: 1 Probe 14 20 427-446 of SEQID NO: 1 Probe 15 20 447-466 of SEQ ID NO: 1 Exon 1 120 1-120 of SEQ IDNO: 6 Exon 2 165 121-285 of SEQ ID NO: 6 Exon 3 183 286-468 of SEQ IDNO: 6 Exon 4a 539 469-1007 of SEQ ID NO: 6 Exon 4b 1059 1008-2066 of SEQID NO: 6 Exon 4c 556 2067-2622 of SEQ ID NO: 6 Exon 4d 960 2623-3582 ofSEQ ID NO: 6

Of course, as will be understood by the person of ordinary skill, amultitude of additional probes can be designed from the same or otherregion of SEQ ID NO:1 as well as from SEQ ID NO:6 and other sequences ofthe present invention.

The nucleic acid probe can be used to probe an appropriate chromosomalor cDNA library by usual hybridization methods to obtain another nucleicacid molecule of the present invention. A chromosomal DNA or cDNAlibrary can be prepared from appropriate cells according to recognizedmethods in the art (cf. Molecular Cloning: A Laboratory Manual, secondedition, edited by Sambrook, Fritsch, & Maniatis, Cold Spring HarborLaboratory, 1989).

In the alternative, chemical synthesis is carried out in order to obtainnucleic acid probes having nucleotide sequences which correspond toN-terminal and C-terminal portions of the PCA3 amino acid sequence.Thus, the synthesized nucleic acid probes can be used as primers in apolymerase chain reaction (PCR) carried out in accordance withrecognized PCR techniques, essentially according to PCR Protocols, AGuide to Methods and Applications, edited by Michael et al., AcademicPress, 1990, utilizing the appropriate chromosomal, cDNA or cell linelibrary to obtain the fragment of the present invention.

One skilled in the art can readily design such probes based on thesequence disclosed herein using methods of computer alignment andsequence analysis known in the art (cf. Molecular Cloning: A LaboratoryManual, second edition, edited by Sambrook, Fritsch, & Maniatis, ColdSpring Harbor Laboratory, 1989).

The hybridization probes of the present invention can be labeled bystandard labeling techniques such as with a radiolabel, enzyme label,fluorescent label, biotin-avidin label, chemiluminescence, and the like.After hybridization, the probes can be visualized using known methods.

The nucleic acid probes of the present invention include RNA, as well asDNA probes, such probes being generated using techniques known in theart.

In one embodiment of the above described method, a nucleic acid probe isimmobilized on a solid support. Examples of such solid supports include,but are not limited to, plastics such as polycarbonate, complexcarbohydrates such as agarose and sepharose, and acrylic resins, such aspolyacrylamide and latex beads. Techniques for coupling nucleic acidprobes to such solid supports are well known in the art.

The test samples suitable for nucleic acid probing methods of thepresent invention include, for example, cells or nucleic acid extractsof cells, or biological fluids. The sample used in the above-describedmethods will vary based on the assay format, the detection method andthe nature of the tissues, cells or extracts to be assayed. Methods forpreparing nucleic acid extracts of cells are well known in the art andcan be readily adapted in order to obtain a sample which is compatiblewith the method utilized.

IV. A Method of Detecting the Presence of PCA3 Nucleic Acid in a Sample

In another embodiment, the present invention relates to a method ofdetecting the presence of PCA3 nucleic acid in a sample comprising a)contacting the sample with the above-described nucleic acid probe, underspecific hybridization conditions such that hybridization occurs, and b)detecting the presence of the probe bound to the nucleic acid molecule.One skilled in the art would select the nucleic acid probe according totechniques known in the art as described above. Samples to be testedinclude but should not be limited to RNA or DNA samples from humantissue.

V. A Kit for Detecting the Presence of PCA3 Nucleic Acid in a Sample

In another embodiment, the present invention relates to a kit fordetecting the presence of PCA3 nucleic acid in a sample comprising atleast one container means having disposed therein the above-describednucleic acid probe. In a preferred embodiment, the kit further comprisesother containers comprising one or more of the following: wash reagentsand reagents capable of detecting the presence of bound nucleic acidprobe. Examples of detection reagents include, but are not limited toradiolabelled probes, enzymatic labeled probes (horse radish peroxidase,alkaline phosphatase), and affinity labeled probes (biotin, avidin, orsteptavidin).

In detail, a compartmentalized kit includes any kit in which reagentsare contained in separate containers. Such containers include smallglass containers, plastic containers or strips of plastic or paper. Suchcontainers allow the efficient transfer of reagents from one compartmentto another compartment such that the samples and reagents are notcross-contaminated and the agents or solutions of each container can beadded in a quantitative fashion from one compartment to another. Suchcontainers will include a container which will accept the test sample, acontainer which contains the probe or primers used in the assay,containers which contain wash reagents (such as phosphate bufferedsaline, Tris-buffers, and the like), and containers which contain thereagents used to detect the hybridized probe, bound antibody, amplifiedproduct, or the like.

One skilled in the art will readily recognize that the nucleic acidprobes described in the present invention can readily be incorporatedinto one of the established kit formats which are well known in the art.

VI. DNA Constructs Comprising a PCA3 Nucleic Acid Molecule and CellsContaining these Constructs

In another embodiment, the present invention relates to a recombinantDNA molecule comprising, 5′ to 3′, a promoter effective to initiatetranscription in a host cell and the above-described nucleic acidmolecules. In another embodiment, the present invention relates to arecombinant DNA molecule comprising a vector and an above-describednucleic acid molecule.

In another embodiment, the present invention relates to a nucleic acidmolecule comprising a transcriptional control region functional in acell, a sequence complimentary to an RNA sequence encoding an amino acidsequence corresponding to the above-described polypeptide, and atranscriptional termination region functional in the cell.

Preferably, the above-described molecules are isolated and/or purifiedDNA molecules.

In another embodiment, the present invention relates to a cell ornon-human organism that contains an above-described nucleic acidmolecule.

In another embodiment, the peptide is purified from cells which havebeen altered to express the peptide.

As used herein, a cell is said to be “altered to express a desiredpeptide” when the cell, through genetic manipulation, is made to producea protein which it normally does not produce or which the cell normallyproduces at low levels. One skilled in the art can readily adaptprocedures for introducing and expressing either genomic, cDNA, orsynthetic sequences into either eukaryotic or prokaryotic cells.

A nucleic acid molecule, such as DNA, is said to be “capable ofexpressing” a polypeptide if it contains nucleotide sequences whichcontain transcriptional and translational regulatory information andsuch sequences are “operably linked” to nucleotide sequences whichencode the polypeptide. An operable linkage is a linkage in which theregulatory DNA sequences and the DNA sequence sought to be expressed areconnected in such a way as to permit gene sequence expression. Theprecise nature of the regulatory regions needed for gene sequenceexpression can vary from organism to organism, but shall in generalinclude a promoter region which, in prokaryotes, contains both thepromoter (which directs the initiation of RNA transcription) as well asthe DNA sequences which, when transcribed into RNA, will signalsynthesis initiation. Such regions will normally include those5′-non-coding sequences involved with initiation of transcription andtranslation, such as the TATA box, capping sequence, CAAT sequence, andthe like.

If desired, the non-coding region 3′ to the PCA3 coding sequence can beobtained by the above-described methods. This region can be retained forits transcriptional termination regulatory sequences, such astermination and polyadenylation. Thus, by retaining the 3′-regionnaturally contiguous to the DNA sequence encoding a PCA3 gene, thetranscriptional termination signals can be provided. Where thetranscriptional termination signals are not satisfactorily functional inthe expression host cell, then a 3′ region functional in the host cellcan be substituted.

Two DNA sequences (such as a promoter region sequence and a PCA3 codingsequence) are said to be operably linked if the nature of the linkagebetween the two DNA sequences does not (1) result in the introduction ofa frame-shift mutation, (2) interfere with the ability of the promoterregion sequence to direct the transcription of a PCA3 coding sequence,or (3) interfere with the ability of the PCA3 coding sequence to betranscribed by the promoter region sequence. Thus, a promoter regionwould be operably linked to a DNA sequence if the promoter were capableof effecting transcription of that DNA sequence.

The present invention encompasses the expression of the PCA3 codingsequence (or a functional derivative thereof) in either prokaryotic oreukaryotic cells. Prokaryotic hosts are, generally, the most efficientand convenient for the production of recombinant proteins and,therefore, are preferred for the expression of the PCA3 coding sequence.

Prokaryotes most frequently are represented by various strains of E.coli. However, other microbial strains can also be used, including otherbacterial strains. In prokaryotic systems, plasmid vectors that containreplication sites and control sequences derived from a speciescompatible with the host can be used. Examples of suitable plasmidvectors include pBR322, pUC18, pUC19, pUC118, pUC119 and the like;suitable phage or bacteriophage vectors include λgt10, λgt11 and thelike; and suitable virus vectors include pMAM-neo, pKRC and the like.Preferably, the selected vector of the present invention has thecapacity to replicate in the selected host cell.

Recognized prokaryotic hosts include bacteria such as E. coli, Bacillus,Streptomyces, Pseudomonas, Salmonella, Serratia, and the like. However,under such conditions, the peptide will not be glycosylated. Theprokaryotic host must be compatible with the replicon and controlsequences in the expression plasmid.

To express PCA3 in a prokaryotic cell, it is necessary to operably linkthe PCA3 coding sequence to a functional prokaryotic promoter. Suchpromoters can be either constitutive or, more preferably, regulatable(i.e., inducible or derepressible). Examples of constitutive promotersinclude the int promoter of bacteriophage λ, the bla promoter of theβ-lactamase gene sequence of pBR322, and the CAT promoter of thechloramphenicol acetyl transferase gene sequence of pBR325, and thelike. Examples of inducible prokaryotic promoters include the majorright and left promoters of bacteriophage λ (P_(L) and P_(R)), the trp,recA, lacZ, lacI, and gal promoters of E. coli, the α-amylase (Ulmanenet al., J. Bacteriol. 162:176-182 (1985)) and the ζ-28-specificpromoters of B. subtilis (Gilman et al., Gene sequence 32:11-20 (1984)),the promoters of the bacteriophages of Bacillus (Gryczan, In: TheMolecular Biology of the Bacilli, Academic Press, Inc., NY (1982)), andStreptomyces promoters (Ward et al., Mol. Gen. Genet. 203:468-478(1986)). Prokaryotic promoters are reviewed by Glick (J. Ind. Microbiol.1:277-282 (1987)); Cenatiempo (Biochimie 68:505-516 (1986)); andGottesman (Ann. Rev. Genet. 18:415-442 (1984)).

Proper expression in a prokaryotic cell also requires the presence of aribosome binding site upstream of the gene sequence-encoding sequence.Such ribosome binding sites are disclosed, for example, by Gold et al.(Ann. Rev. Microbiol. 35:365-404 (1981)).

The selection of control sequences, expression vectors, transformationmethods, and the like, are dependent on the type of host cell used toexpress the gene. As used herein, “cell”, “cell line”, and “cellculture” can be used interchangeably and all such designations includeprogeny. Thus, the words “transformants” or “transformed cells” includethe primary subject cell and cultures derived therefrom, without regardto the number of transfers. It is also understood that all progeny cannot be precisely identical in DNA content, due to deliberate orinadvertent mutations. However, as defined, mutant progeny have the samefunctionality as that of the originally transformed cell.

Host cells which can be used in the expression systems of the presentinvention are not strictly limited, provided that they are suitable foruse in the expression of the PCA3 peptide of interest. Suitable hostsinclude eukaryotic cells.

Preferred eukaryotic hosts include, for example, yeast, fungi, insectcells, mammalian cells either in vivo, or in tissue culture. Preferredmammalian cells include HeLa cells, cells of fibroblast origin such asVERO or CHO-K1, or cells of lymphoid origin and their derivatives.

In addition, plant cells are also available as hosts, and controlsequences compatible with plant cells are available, such as thecauliflower mosaic virus 3S and 19S, and nopaline synthase promoter andpolyadenylation signal sequences.

Another preferred host is an insect cell, for example Drosophila larvae.Using insect cells as hosts, the Drosophila alcohol dehydrogenasepromoter can be used, Rubin, Science 240:1453-1459 (1988).Alternatively, baculovirus vectors can be engineered to express largeamounts of PCA3 in insect cells (Jasny, Science 238:1653 (1987); Milleret al., In: Genetic Engineering (1986), Setlow, J. K., et al., eds.,Plenum, Vol. 8, pp. 277-297).

Different host cells have characteristic and specific mechanisms for thetranslational and post-translational processing and modification (e.g.,glycosylation, cleavage) of proteins. Appropriate cell lines or hostsystems can be chosen to ensure the desired modification and processingof the foreign protein expressed.

Any of a series of yeast gene sequence expression systems can beutilized which incorporate promoter and termination elements from theactively expressed gene sequences coding for glycolytic enzymes. Theseenzymes are produced in large quantities when yeast are grown in mediumsrich in glucose. Known glycolytic gene sequences can also provide veryefficient transcriptional control signals.

Yeast provides substantial advantages in that it can also carry outpost-translational peptide modifications. A number of recombinant DNAstrategies exist which utilize strong promoter sequences and high copynumber of plasmids which can be utilized for production of the desiredproteins in yeast. Yeast recognizes leader sequences on cloned mammaliangene sequence products and secretes peptides bearing leader sequences(i.e., pre-peptides). For a mammalian host, several possible vectorsystems are available for the expression of PCA3.

A wide variety of transcriptional and translational regulatory sequencescan be employed, depending upon the nature of the host. Thetranscriptional and translational regulatory signals can be derived fromviral sources, such as adenovirus, bovine papilloma virus, simian virus,or the like, where the regulatory signals are associated with aparticular gene sequence which has a high level of expression.Alternatively, promoters from mammalian expression products, such asactin, collagen, myosin, and the like, can be employed. Transcriptionalinitiation regulatory signals can be selected which allow for repressionor activation, so that expression of the gene sequences can bemodulated. Of interest are regulatory signals which aretemperature-sensitive so that by varying the temperature, expression canbe repressed or initiated, or are subject to chemical (such asmetabolite) regulation.

As discussed above, expression of PCA3 in eukaryotic hosts requires theuse of eukaryotic regulatory regions. Such regions will, in general,include a promoter region sufficient to direct the initiation of RNAsynthesis. Preferred eukaryotic promoters include, for example, thepromoter of the mouse metallothionein I gene sequence (Hamer et al., J.Mol. Appl. Gen. 1:273-288 (1982)); the TK promoter of Herpes virus(McKnight, Cell 31:355-365 (1982)); the SV40 early promoter (Benoist etal., Nature (London) 290:304-310 (1981)); the yeast gal4 gene sequencepromoter (Johnston et al., Proc. Natl. Acad. Sci. (USA) 79:6971-6975(1982); Silver et al., Proc. Natl. Acad. Sci. (USA) 81:5951-5955 (1984))and the CMV immediate-early gene promoter (Thomsen et al., Proc. Natl.Acad. Sci. (USA) 81:659-663 (1984).

As is widely known, translation of eukaryotic mRNA is initiated at thecodon which encodes the first methionine. For this reason, it ispreferable to ensure that the linkage between a eukaryotic promoter anda PCA3 coding sequence does not contain any intervening codons which arecapable of encoding a methionine (i.e., AUG). The presence of suchcodons results either in a formation of a fusion protein (if the AUGcodon is in the same reading frame as the PCA3 coding sequence) or aframe-shift mutation (if the AUG codon is not in the same reading frameas the PCA3 coding sequence).

A PCA3 nucleic acid molecule and an operably linked promoter can beintroduced into a recipient prokaryotic or eukaryotic cell either as anon-replicating DNA (or RNA) molecule, which can either be a linearmolecule or, more preferably, a closed covalent circular molecule. Sincesuch molecules are incapable of autonomous replication, the expressionof the gene can occur through the transient expression of the introducedsequence. Alternatively, permanent expression can occur through theintegration of the introduced DNA sequence into the host chromosome.

In one embodiment, a vector is employed which is capable of integratingthe desired gene sequences into the host cell chromosome. Cells whichhave stably integrated the introduced DNA into their chromosomes can beselected by also introducing one or more markers which allow forselection of host cells which contain the expression vector. The markercan provide for prototrophy to an auxotrophic host, biocide resistance,e.g., antibiotics, or heavy metals, such as copper, or the like. Theselectable marker gene sequence can either be directly linked to the DNAgene sequences to be expressed, or introduced into the same cell byco-transfection. Additional elements can also be needed for optimalsynthesis of single chain binding protein mRNA. These elements caninclude splice signals, as well as transcription promoters, enhancersignal sequences, and termination signals. cDNA expression vectorsincorporating such elements include those described by Okayama, Molec.Cell. Biol. 3:280 (1983).

In a preferred embodiment, the introduced nucleic acid molecule will beincorporated into a plasmid or viral vector capable of autonomousreplication in the recipient host. Any of a wide variety of vectors canbe employed for this purpose. Factors of importance in selecting aparticular plasmid or viral vector include: the ease with whichrecipient cells that contain the vector can be recognized and selectedfrom those recipient cells which do not contain the vector; the numberof copies of the vector which are desired in a particular host; andwhether it is desirable to be able to “shuttle” the vector between hostcells of different species. Preferred prokaryotic vectors includeplasmids such as those capable of replication in E. coli (such as, forexample, pBR322, ColE1, pSC101, pACYC 184, πVX. Such plasmids are, forexample, disclosed by Sambrook (cf. Molecular Cloning: A LaboratoryManual, second edition, edited by Sambrook, Fritsch, & Maniatis, ColdSpring Harbor Laboratory, 1989). Bacillus plasmids include pC194, pC221,pT127, and the like. Such plasmids are disclosed by Gryczan (In: TheMolecular Biology of the Bacilli, Academic Press, NY (1982), pp.307-329). Suitable Streptomyces plasmids include plJ101 (Kendall et al.,J. Bacteriol. 169:4177-4183 (1987)), and streptomyces bacteriophagessuch as φC31 (Chater et al., In: Sixth International Symposium onActinomycetales Biology, Akademiai Kaido, Budapest, Hungary (1986), pp.45-54). Pseudomonas plasmids are reviewed by John et al. (Rev. Infect.Dis. 8:693-704 (1986)), and Izaki (Jpn. J. Bacteriol. 33:729-742(1978)).

Preferred eukaryotic plasmids include, for example, BPV, vaccinia, SV40,2-micron circle, and the like, or their derivatives. Such plasmids arewell known in the art (Botstein et al., Miami Wntr. Symp. 19:265-274(1982); Broach, In: The Molecular Biology of the Yeast Saccharomyces:Life Cycle and Inheritance, Cold Spring Harbor Laboratory, Cold SpringHarbor, N.Y., p. 445-470 (1981); Broach, Cell 28:203-204 (1982); Bollonet al., J. Clin. Hematol. Oncol. 10:39-48 (1980); Maniatis, In: CellBiology: A Comprehensive Treatise, Vol. 3, Gene Sequence Expression,Academic Press, NY, pp. 563-608 (1980)).

Once the vector or nucleic acid molecule containing the construct(s) hasbeen prepared for expression, the DNA construct(s) can be introducedinto an appropriate host cell by any of a variety of suitable means,i.e., transformation, transfection, conjugation, protoplast fusion,electroporation, particle gun technology, calciumphosphate-precipitation, direct microinjection, and the like. After theintroduction of the vector, recipient cells are grown in a selectivemedium, which selects for the growth of vector-containing cells.Expression of the cloned gene molecule(s) results in the production ofPCA3. This can take place in the transformed cells as such, or followingthe induction of these cells to differentiate (for example, byadministration of bromodeoxyuracil to neuroblastoma cells or the like).

VII. An Antibody Having Binding Affinity to a PCA3 Polypeptide and aHybridoma Containing the Antibody

In another embodiment, the present invention relates to an antibodyhaving binding affinity specifically to a PCA3 polypeptide as describedabove or specifically to a PCA3 polypeptide binding fragment thereof. Anantibody binds specifically to a PCA3 polypeptide or binding fragmentthereof if it does not bind to non-PCA3 polypeptides. Those which bindselectively to PCA3 would be chosen for use in methods which couldinclude, but should not be limited to, the analysis of altered PCA3expression in tissue containing PCA3.

The PCA3 proteins of the present invention can be used in a variety ofprocedures and methods, such as for the generation of antibodies, foruse in identifying pharmaceutical compositions, and for studyingDNA/protein interaction.

The PCA3 peptide of the present invention can be used to produceantibodies or hybridomas. One skilled in the art will recognize that ifan antibody is desired, such a peptide would be generated as describedherein and used as an immunogen.

The antibodies of the present invention include monoclonal andpolyclonal antibodies, as well as fragments of these antibodies. Theinvention further includes single chain antibodies. Antibody fragmentswhich contain the idiotype of the molecule can be generated by knowntechniques. For example, such fragments include but are not limited to:the F(ab′)₂ fragment; the Fab′ fragments, Fab fragments, and Fvfragments.

Of special interest to the present invention are antibodies to PCA3which are produced in humans, or are “humanized” (i.e. non-immunogenicin a human) by recombinant or other technology. Humanized antibodies canbe produced, for example by replacing an immunogenic portion of anantibody with a corresponding, but non-immunogenic portion (i.e.chimeric antibodies) (Robinson, R. R. et al., International PatentPublication PCT/US86/02269; Akira, K. et al., European PatentApplication 184,187; Taniguchi, M., European Patent Application 171,496;Morrison, S. L. et al., European Patent Application 173,494; Neuberger,M. S. et al., PCT Application WO 86/01533; Cabilly, S. et al., EuropeanPatent Application 125,023; Better, M. et al., Science 240:1041-1043(1988); Liu, A. Y. et al., Proc. Natl. Acad. Sci. USA 84:3439-3443(1987); Liu, A. Y. et al., J. Immunol. 139:3521-3526 (1987); Sun, L. K.et al., Proc. Natl. Acad. Sci. USA 84:214-218 (1987); Nishimura, Y. etal., Canc. Res. 47:999-1005 (1987); Wood, C. R. et al., Nature314:446-449 (1985)); Shaw et al., J. Natl. Cancer Inst. 80:1553-1559(1988). General reviews of “humanized” chimeric antibodies are providedby Morrison, S. L. (Science, 229:1202-1207 (1985)) and by Oi, V. T. etal., BioTechniques 4:214 (1986)). Suitable “humanized” antibodies can bealternatively produced by CDR or CEA substitution (Jones, P. T. et al.,Nature 321:552-525 (1986); Verhoeyan et al., Science 239:1534 (1988);Beidler, C. B. et al., J. Immunol. 141:4053-4060 (1988)).

In another embodiment, the present invention relates to a hybridomawhich produces the above-described monoclonal antibody. A hybridoma isan immortalized cell line which is capable of secreting a specificmonoclonal antibody.

In general, techniques for preparing monoclonal antibodies andhybridomas are well known in the art (Campbell, “Monoclonal AntibodyTechnology: Laboratory Techniques in Biochemistry and MolecularBiology,” Elsevier Science Publishers, Amsterdam, The Netherlands(1984); St. Groth et al., J. Immunol. Methods 35:1-21 (1980)).

Any animal (mouse, rabbit, and the like) which is known to produceantibodies can be immunized with the selected polypeptide. Methods forimmunization are well known in the art. Such methods includesubcutaneous or interperitoneal injection of the polypeptide. Oneskilled in the art will recognize that the amount of polypeptide usedfor immunization will vary based on the animal which is immunized, theantigenicity of the polypeptide and the site of injection.

The polypeptide can be modified or administered in an adjuvant in orderto increase the peptide antigenicity. Methods of increasing theantigenicity of a polypeptide are well known in the art. Such proceduresinclude coupling the antigen with a heterologous protein (such asglobulin or β-galactosidase) or through the inclusion of an adjuvantduring immunization.

For monoclonal antibodies, spleen cells from the immunized animals areremoved, fused with myeloma cells, and allowed to become monoclonalantibody producing hybridoma cells.

Any one of a number of methods well known in the art can be used toidentify the hybridoma cell which produces an antibody with the desiredcharacteristics. These include screening the hybridomas with an ELISAassay, western blot analysis, or radioimmunoassay (Lutz et al., Exp.Cell Res. 175:109-124 (1988)).

Hybridomas secreting the desired antibodies are cloned and the class andsubclass is determined using procedures known in the art (Campbell,Monoclonal Antibody Technology: Laboratory Techniques in Biochemistryand Molecular Biology, supra (1984)).

For polyclonal antibodies, antibody containing antisera is isolated fromthe immunized animal and is screened for the presence of antibodies withthe desired specificity using one of the above-described procedures.

In another embodiment of the present invention, the above-describedantibodies are detectably labeled. Antibodies can be detectably labeledthrough the use of radioisotopes, affinity labels (such as biotin,avidin, and the like), enzymatic labels (such as horse radishperoxidase, alkaline phosphatase, and the like) fluorescent labels (suchas FITC or rhodamine, and the like), paramagnetic atoms, and the like.Procedures for accomplishing such labeling are well-known in the art,for example, see (Sternberger et al., J. Histochem. Cytochem. 18:315(1970); Bayer et al., Meth. Enzym. 62:308 (1979); Engval et al.,Immunol. 109:129 (1972); Goding, J. Immunol. Meth. 13:215 (1976)). Thelabeled antibodies of the present invention can be used for in vitro, invivo, and in situ assays to identify cells or tissues which express aspecific peptide.

In another embodiment of the present invention the above-describedantibodies are immobilized on a solid support. Examples of such solidsupports include plastics such as polycarbonate, complex carbohydratessuch as agarose and sepharose, acrylic resins and such as polyacrylamideand latex beads. Techniques for coupling antibodies to such solidsupports are well known in the art (Weir et al., “Handbook ofExperimental Immunology” 4th Ed., Blackwell Scientific Publications,Oxford, England, Chapter 10 (1986); Jacoby et al., Meth. Enzym. 34Academic Press, N.Y. (1974)). The immobilized antibodies of the presentinvention can be used for in vitro, in vivo, and in situ assays as wellas in immunochromatography.

Furthermore, one skilled in the art can readily adapt currentlyavailable procedures, as well as the techniques, methods and kitsdisclosed above with regard to antibodies, to generate peptides capableof binding to a specific peptide sequence in order to generaterationally designed antipeptide peptides, for example see Hurby et al.,“Application of Synthetic Peptides Antisense Peptides”, In SyntheticPeptides, A User's Guide, W.H. Freeman, NY, pp. 289-307 (1992), andKaspczak et al., Biochemistry 28:9230-8 (1989).

Anti-peptide peptides can be generated in one of two fashions. First,the anti-peptide peptides can be generated by replacing the basic aminoacid residues found in the PCA3 peptide sequence with acidic residues,while maintaining hydrophobic and uncharged polar groups. For example,lysine, arginine, and/or histidine residues are replaced with asparticacid or glutamic acid and glutamic acid residues are replaced by lysine,arginine or histidine.

VIII. A Method of Detecting a PCA3 Polypeptide or Antibody in a Sample

In another embodiment, the present invention relates to a method ofdetecting a PCA3 polypeptide in a sample, comprising: a) contacting thesample with an above-described antibody (or protein), under conditionssuch that immunocomplexes form, and b) detecting the presence of theantibody bound to the polypeptide. In detail, the methods compriseincubating a test sample with one or more of the antibodies of thepresent invention and assaying whether the antibody binds to the testsample. Altered levels of PCA3 in a sample as compared to normal levelscan indicate a specific disease (ex. prostate cancer).

In a further embodiment, the present invention relates to a method ofdetecting a PCA3 antibody in a sample, comprising: a) contacting thesample with an above-described PCA3 protein, under conditions such thatimmunocomplexes form, and b) detecting the presence of the protein boundto the antibody or antibody bound to the protein. In detail, the methodscomprise incubating a test sample with one or more of the proteins ofthe present invention and assaying whether the antibody binds to thetest sample.

Conditions for incubating an antibody with a test sample vary.Incubation conditions depend on the format employed in the assay, thedetection methods employed, and the type and nature of the antibody usedin the assay. One skilled in the art will recognize that any one of thecommonly available immunological assay formats (such asradioimmunoassays, enzyme-linked immunosorbent assays, diffusion basedOuchterlony, or rocket immunofluorescent assays) can readily be adaptedto employ the antibodies of the present invention. Examples of suchassays can be found in Chard, An Introduction to Radioimmunoassay andRelated Techniques, Elsevier Science Publishers, Amsterdam, TheNetherlands (1986); Bullock et al., Techniques in Immunocytochemistry,Academic Press, Orlando, Fla. Vol. 1 (1982), Vol. 2 (1983), Vol. 3(1985); Tijssen, Practice and Theory of Enzyme Immunoassays: LaboratoryTechniques in Biochemistry and Molecular Biology, Elsevier SciencePublishers, Amsterdam, The Netherlands (1985).

The immunological assay test samples of the present invention includecells, protein or membrane extracts of cells, or biological fluids suchas blood, serum, plasma, or urine. The test sample used in theabove-described method will vary based on the assay format, nature ofthe detection method and the tissues, cells or extracts used as thesample to be assayed. Methods for preparing protein extracts or membraneextracts of cells are well known in the art and can be readily beadapted in order to obtain a sample which is capable with the systemutilized.

IX. A Diagnostic Kit Comprising PCA3 Protein or Antibody

In another embodiment of the present invention, a kit is provided whichcontains all the necessary reagents to carry out the previouslydescribed methods of detection.

The kit can comprise: i) a first container means containing anabove-described antibody, and ii) second container means containing aconjugate comprising a binding partner of the antibody and a label.

The kit can comprise: i) a first container means containing anabove-described protein, and preferably, ii) second container meanscontaining a conjugate comprising a binding partner of the protein and alabel. More specifically, a diagnostic kit comprises PCA3 protein asdescribed above, to detect antibodies in the serum of potentiallyinfected animals or humans.

In another preferred embodiment, the kit further comprises one or moreother containers comprising one or more of the following: wash reagentsand reagents capable of detecting the presence of bound antibodies.Examples of detection reagents include, but are not limited to, labeledsecondary antibodies, or in the alternative, if the primary antibody islabeled, the chromophoric, enzymatic, or antibody binding reagents whichare capable of reacting with the labeled antibody. The compartmentalizedkit can be as described above for nucleic acid probe kits.

One skilled in the art will readily recognize that the antibodiesdescribed in the present invention can readily be incorporated into oneof the established kit formats which are well known in the art.

X. Diagnostic Screening

It is to be understood that although the following discussion isspecifically directed to human patients, the teachings are alsoapplicable to any animal that expresses PCA3.

The diagnostic and screening methods of the invention are especiallyuseful for a patient suspected of being at risk for developing a diseaseassociated with an altered expression level of PCA3 based on familyhistory, or a patient in wt is desired to diagnose a PCA3-relateddisease (ex. prostate cancer).

According to the invention, presymptomatic screening of an individual inf such screening is now possible using DNA encoding the PCA3 protein orthe PCA3 gene of the invention or fragments thereof. The screeningmethod of the invention allows a presymptomatic diagnosis, includingprenatal diagnosis, of the presence of a missing or aberrant PCA3 genein individuals, and thus an opinion concerning the likelihood that suchindividual would develop or has developed a PCA3-associated disease.This is especially valuable for the identification of carriers ofaltered or missing PCA3 genes, for example, from individuals with afamily history of a PCA3-associated disease. Early diagnosis is alsodesired to maximize appropriate timely intervention.

In one preferred embodiment of the method of screening, a tissue samplewould be taken from such individual, and screened for (1) the presenceof the “normal” PCA3 gene; (2) the presence of PCA3 mRNA and/or (3) thepresence of PCA3 protein. The normal human gene can be characterizedbased upon, for example, detection of restriction digestion patterns in“normal” versus the patient's DNA, including RFLP analysis, using DNAprobes prepared against the PCA3 sequence (or a functional fragmentthereof) taught in the invention. Similarly, PCA3 mRNA can becharacterized and compared to normal PCA3 mRNA (a) levels and/or (b)size as found in a human population not at risk of developingPCA3-associated disease using similar probes. Lastly, PCA3 protein canbe (a) detected and/or (b) quantitated using a biological assay for PCA3activity or using an immunological assay and PCA3 antibodies. Whenassaying PCA3 protein, the immunological assay is preferred for itsspeed. An (1) aberrant PCA3 DNA size pattern, and/or (2) aberrant PCA3mRNA sizes or levels and/or (3) aberrant PCA3 protein levels wouldindicate that the patient is at risk for developing a PCA3-associateddisease.

More specifically, a method of diagnosing the presence or predispositionto develop prostate cancer in a patient is provided herein.

The screening and diagnostic methods of the invention do not requirethat the entire PCA3 DNA coding sequence be used for the probe. Rather,it is only necessary to use a fragment or length of nucleic acid that issufficient to detect the presence of the PCA3 gene in a DNA preparationfrom a normal or affected individual, the absence of such gene, or analtered physical property of such gene (such as a change inelectrophoretic migration pattern). Preferably, any of the probes asdescribed above are used.

Prenatal diagnosis can be performed when desired, using any known methodto obtain fetal cells, including amniocentesis, chorionic villoussampling (CVS), and fetoscopy. Prenatal chromosome analysis can be usedto determine if the portion of the chromosome possessing the normal PCA3gene is present in a heterozygous state.

XI. Therapeutic Treatments A. Therapeutic Nucleic Acids

A therapeutic nucleic acid as a therapeutic agent can have, but is notlimited to, at least one of the following therapeutic effects on atarget cell: inhibiting transcription of a DNA sequence; inhibitingtranslation of an RNA sequence; inhibiting reverse transcription of anRNA or DNA sequence; inhibiting a post-translational modification of aprotein; inducing transcription of a DNA sequence; inducing translationof an RNA sequence; inducing reverse transcription of an RNA or DNAsequence; inducing a post-translational modification of a protein;transcription of the nucleic acid as an RNA; translation of the nucleicacid as a protein or enzyme; and incorporating the nucleic acid into achromosome of a target cell for constitutive or transient expression ofthe therapeutic nucleic acid.

Therapeutic effects of therapeutic nucleic acids can include, but arenot limited to: turning off a defective gene or processing theexpression thereof, such as antisense RNA or DNA; inhibiting viralreplication or synthesis; gene therapy as expressing a heterologousnucleic acid encoding a therapeutic protein or correcting a defectiveprotein; modifying a defective or underexpression of an RNA such as anhnRNA, an mRNA, a tRNA, or an rRNA; encoding a drug or prodrug, or anenzyme that generates a compound as a drug or prodrug in pathological ornormal cells expressing the chimeric receptor; and any other knowntherapeutic effects.

In the method of treating a PCA3-associated disease (preferably,prostate cancer) in a patient in need of such treatment, a PCA3 genewhich is not indicative of a disease state can be provided to the cellsof such patient in a manner and amount that permits the expression ofthe PCA3 protein provided by such gene, for a time and in a quantitysufficient to treat such patient. Preferably, gene replacement (“knockout”) technology is used that would replace the disease causing PCA3gene with a PCA3 gene which does not cause disease (specifically,prostate cancer).

Included as well in the invention are pharmaceutical compositionscomprising an effective amount of at least one PCA3 antisenseoligonucleotide, in combination with a pharmaceutically acceptablecarrier. Such antisense oligos include, but are not limited to, at leastone nucleotide sequence of 12-500 bases in length which is complementaryto PCA3 exons 1, 2, 3, 4a-4-d; a DNA sequence of SEQ ID NO:1, 3, 4, or6; or a DNA sequence encoding at least 4 amino acids of SEQ ID NO:2 orSEQ ID NO:7.

Alternatively, the PCA3 nucleic acid can be combined with a lipophiliccarrier such as any one of a number of sterols including cholesterol,cholate and deoxycholic acid. A preferred sterol is cholesterol.

The PCA3 gene therapy nucleic acids and the pharmaceutical compositionsof the invention can be administered by any means that achieve theirintended purpose. For example, administration can be by parenteral,subcutaneous, intravenous, intramuscular, intra-peritoneal, ortransdermal routes. The dosage administered will be dependent upon theage, health, and weight of the recipient, kind of concurrent treatment,if any, frequency of treatment, and the nature of the effect desired.

Compositions within the scope of this invention include all compositionswherein the PCA3 antisense oligonucleotide is contained in an amounteffective to achieve decreased expression of at least one PCA3 gene.While individual needs vary, determination of optimal ranges ofeffective amounts of each component is within the skill of the art.Typically, the PCA3 nucleic acid can be administered to mammals, e.g.humans, at a dose of 0.005 to 1 mg/kg/day, or an equivalent amount ofthe pharmaceutically acceptable salt thereof, per day of the body weightof the mammal being treated.

Suitable formulations for parenteral administration include aqueoussolutions of the PCA3 nucleic acid in water-soluble form, for example,water-soluble salts. In addition, suspensions of the active compounds asappropriate oily injection suspensions can be administered. Suitablelipophilic solvents or vehicles include fatty oils, for example, sesameoil, or synthetic fatty acid esters, for example, ethyl oleate ortriglycerides. Aqueous injection suspensions can contain substanceswhich increase the viscosity of the suspension include, for example,sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally,the suspension can also contain stabilizers.

Many vector systems are known in the art to provide such delivery tohuman patients in need of a gene or protein missing from the cell. Forexample, retrovirus systems can be used, especially modified retrovirussystems and especially herpes simplex virus systems (Gage et al., U.S.Pat. No. 5,082,670). Such methods are provided for, in, for example, theteachings of Breakefield, X. A. et al., The New Biologist 3:203-218(1991); Huang, Q. et al., Experimental Neurology 115:303-316 (1992);WO93/03743; WO90/0944; Taylor, WO 92/06693; Mulligan, R. C., Science260:926-932 (1993); and Brown et al., “Retroviral Vectors,” in DNACloning: A Practical Approach, Volume 3, IRL Press, Washington, D.C.(1987). Delivery of a DNA sequence encoding a normally expressed PCA3protein will effectively replace the PCA3 gene responsible for thedisease state (ex. prostate cancer).

The means by which the vector carrying the nucleic acid can beintroduced into the cell include but is not limited to, microinjection,electroporation, transduction, or transfection using DEAE-Dextran,lipofection, calcium phosphate or other procedures known to one skilledin the art (Molecular Cloning, A Laboratory Manual, Sambrook et al.,eds., Cold Spring Harbor Press, Plainview, N.Y. (1989)).

In another embodiment of this invention, a normal PCA3 gene is expressedas a recombinant gene in a cell, so that the cells can be transplantedinto a mammal, preferably a human in need of gene therapy. To providegene therapy to an individual, a genetic sequence which encodes for allor part of the PCA3 gene is inserted into a vector and introduced into ahost cell.

Further gene therapy methods which can be used to transfer nucleic acidto a patient are set forth in Chatterjee and Wong, Current Topics inMicrobiol. and Immuno., 218: 61-73 (1996); Zhang, J. Mol. Med.74:191-204 (1996); Schmidt-Wolf and Schmidt-Wolf, J. of Hematotherapy4:551-561 (1995); Shaughnessy et al., Seminars in Oncology 23(1):159-171 (1996); and Dunbar Annu. Rev. Med. 47:11-20 (1996).

Specificity for gene expression in prostate cancer cells can beconferred by using appropriate cell-specific regulatory sequences, suchas cell-specific enhancers and promoters.

Thus, gene therapy can be used to alleviate PCA3 related pathology byinhibiting the inappropriate expression of a particular form of PCA3.Moreover, gene therapy can be used to alleviate such pathologies byproviding the appropriate expression level of a particular form of PCA3.In this case, particular PCA3 nucleic acid sequences can be coded by DNAor RNA constructs which are administered in the form of viruses, asdescribed above.

B. Antagonists and Agonists of PCA3

The ability of antagonists and agonists of PCA3 to interfere or enhancethe activity of PCA3 can be evaluated with cells containing PCA3. Anassay for PCA3 activity in cells can be used to determine thefunctionality of the PCA3 protein in the presence of an agent which mayact as antagonist or agonist, and thus, agents that interfere or enhancethe activity of PCA3 are identified.

The agents screened in the assays can be, but are not limited to,antibodies, peptides, carbohydrates, vitamin derivatives, or otherpharmaceutical agents. These agents can be selected and screened 1) atrandom, 2) by a rational selection or 3) by design using for example,protein or ligand modeling techniques (preferably, computer modeling).

For random screening, agents such as antibodies, peptides,carbohydrates, pharmaceutical agents and the like are selected at randomand are assayed for their ability to bind to or stimulate/block theactivity of the PCA3 protein.

Alternatively, agents may be rationally selected or designed. As usedherein, an agent is said to be “rationally selected or designed” whenthe agent is chosen based on the configuration of the PCA3 protein.

In one embodiment, the present invention relates to a method ofscreening for an antagonist or agonist which stimulates or blocks theactivity of PCA3 comprising:

(a) incubating a cell expressing PCA3 with an agent to be tested; and

(b) assaying the cell for the activity of the PCA3 protein by measuringthe agents effect on ATP binding of PCA3.

Any cell may be used in the above assay so long as it expresses afunctional form of PCA3 and the PCA3 activity can be measured. Thepreferred expression cells are eukaryotic cells or organisms. Such cellscan be modified to contain DNA sequences encoding PCA3 using routineprocedures known in the art. Alternatively, one skilled in the art canintroduce mRNA encoding the PCA3 protein directly into the cell.

Using PCA3 ligands (ligands including antagonists and agonists asdescribed above) the present invention further provides a method formodulating the activity of the PCA3 protein in a cell. In general,ligands (antagonists and agonists) which have been identified to blockor stimulate the activity of PCA3 can be formulated so that the ligandcan be contacted with a cell expressing a PCA3 protein in vivo. Thecontacting of such a cell with such a ligand results in the in vivomodulation of the activity of the PCA3 proteins. So long as aformulation barrier or toxicity barrier does not exist, ligandsidentified in the assays described above will be effective for in vivouse.

In another embodiment, the present invention relates to a method ofadministering PCA3 or a PCA3 ligand (including PCA3 antagonists andagonists) to an animal (preferably, a mammal (specifically, a human)) inan amount sufficient to effect an altered level of PCA3 in the animal.The administered PCA3 or PCA3 ligand could specifically effect PCA3associated functions. Further, since PCA3 is expressed in prostaticcancer cells, administration of PCA3 or PCA3 ligand could be used toalter PCA3 levels in such cells.

One skilled in the art will appreciate that the amounts to beadministered for any particular treatment protocol can readily bedetermined. The dosage should not be so large as to cause adverse sideeffects, such as unwanted cross-reactions, anaphylactic reactions, andthe like. Generally, the dosage will vary with the age, condition, sexand extent of disease in the patient, counter indications, if any, andother such variables, to be adjusted by the individual physician. Dosagecan vary from 0.001 mg/kg to 50 mg/kg of PCA3 or PCA3 ligand, in one ormore administrations daily, for one or several days. PCA3 or PCA3 ligandcan be administered parenterally by injection or by gradual perfusionover time. It can be administered intravenously, intraperitoneally,intramuscularly, or subcutaneously.

Preparations for parenteral administration include sterile or aqueous ornon-aqueous solutions, suspensions, and emulsions. Examples ofnon-aqueous solvents are propylene glycol, polyethylene glycol,vegetable oils such as olive oil, and injectable organic esters such asethyl oleate. Aqueous carriers include water, alcoholic/aqueoussolutions, emulsions or suspensions, including saline and bufferedmedia. Parenteral vehicles include sodium chloride solution, Ringer'sdextrose and sodium chloride, lactated Ringer's, or fixed oils.Intravenous vehicles include fluid and nutrient replenishers,electrolyte replenishers, such as those based on Ringer's dextrose, andthe like. Preservatives and other additives can also be present, suchas, for example, antimicrobials, antioxidants, chelating agents, inertgases and the like. See, generally, Remington's Pharmaceutical Science,16th Ed., Mack Eds. (1980).

In another embodiment, the present invention relates to a pharmaceuticalcomposition comprising PCA3 or PCA3 ligand in an amount sufficient toalter PCA3 associated activity, and a pharmaceutically acceptablediluent, carrier, or excipient. Appropriate concentrations and dosageunit sizes can be readily determined by one skilled in the art asdescribed above (See, for example, Remington's Pharmaceutical Sciences(16th ed., Osol, A., Ed., Mack, Easton Pa. (1980) and WO 91/19008).

C. Immunotherapy

The present invention provides the above-described PCA3 antibodies(preferably, PCA3 murine antibodies and chimeric PCA3 murine-humanantibodies, and fragments and regions thereof) which inhibit orneutralize PCA3 biological activity in vivo and are specific for PCA3.These antibodies can be used for therapeutic purposes in subjects havingpathologies or conditions associated with the presence of aberrant PCA3expression. Antibodies, and fragments, regions and derivatives thereof,of the present invention preferably contain at least one region whichrecognizes an epitope of PCA3 which has inhibiting and/or neutralizingbiological activity in vivo.

Treatment comprises parenterally administering a single or multipledoses of the antibody, fragment or derivative. Preferred for humanpharmaceutical use are high affinity potent PCA3-inhibiting and/orneutralizing murine and chimeric antibodies, fragments and regions ofthis invention.

Monoclonal antibodies of the present invention may be administered byany means that enables the active agent to reach the agent's site ofaction in the body of a mammal. Because proteins are subject to beingdigested when administered orally, parenteral administration, i.e.,intravenous, subcutaneous, intramuscular, would ordinarily be used tooptimize absorption.

Monoclonal antibodies of the present invention may be administeredeither as individual therapeutic agents or in combination with othertherapeutic agents. They can be administered alone, but are generallyadministered with a pharmaceutical carrier selected on the basis of thechosen route of administration and standard pharmaceutical practice.

The dosage administered will, of course, vary depending upon knownfactors such as the pharmacodynamic characteristics of the particularagent, and its mode and route of administration; age, health, and weightof the recipient; nature and extent of symptoms, kind of concurrenttreatment, frequency of treatment, and the effect desired. Usually adaily dosage of active ingredient can be about 0.1 to 100 milligrams perkilogram of body weight. Ordinarily 0.5 to 50, and preferably 1 to 10milligrams per kilogram per day given in divided doses 1 to 6 times aday or in sustained release form is effective to obtain desired results.

Dosage forms (composition) suitable for internal administrationgenerally contain from about 1 milligram to about 500 milligrams ofactive ingredient per unit. In these pharmaceutical compositions theactive ingredient will ordinarily be present in an amount of about0.5-95% by weight based on the total weight of the composition.

For parenteral administration, the antibody can be formulated as asolution, suspension, emulsion or lyophilized powder in association witha pharmaceutically acceptable parenteral vehicle. Examples of suchvehicles are water, saline, Ringer's solution, dextrose solution, and 5%human serum albumin. Liposomes and nonaqueous vehicles such as fixedoils may also be used. The vehicle or lyophilized powder may containadditives that maintain isotonicity (e.g., sodium chloride, mannitol)and chemical stability (e.g., buffers and preservatives). Theformulation is sterilized by commonly used techniques.

Suitable pharmaceutical carriers are described in the most recentedition of Remington's Pharmaceutical Sciences, A. Osol, a standardreference text in this field.

The murine and chimeric antibodies, fragments and regions of thisinvention, their fragments, and derivatives can be used therapeuticallyas immunoconjugates (see for review: Dillman, R. O., Ann. Int. Med.111:592-603 (1989)). They can be coupled to cytotoxic proteins,including, but not limited to Ricin-A, Pseudomonas toxin, and Diphtheriatoxin. Toxins conjugated to antibodies or other ligands, are known inthe art (see, for example, Olsnes, S. et al., Immunol. Today 10:291-295(1989)). Plant and bacterial toxins typically kill cells by disruptingthe protein synthetic machinery.

The antibodies of this invention can be conjugated to additional typesof therapeutic moieties including, but not limited to, radionuclides,cytotoxic agents and drugs. Examples of radionuclides which can becoupled to antibodies and delivered in vivo to sites of antigen include²¹²Bi, ¹³¹I, ¹⁸⁶Re, and ⁹⁰Y, which list is not intended to beexhaustive. The radionuclides exert their cytotoxic effect by locallyirradiating the cells, leading to various intracellular lesions, as isknown in the art of radiotherapy.

Cytotoxic drugs which can be conjugated to antibodies and subsequentlyused for in vivo therapy include, but are not limited to, daunorubicin,doxorubicin, methotrexate, and Mitomycin C. Cytotoxic drugs interferewith critical cellular processes including DNA, RNA, and proteinsynthesis. For a fuller exposition of these classes of drugs which areknown in the art, and their mechanisms of action, see Goodman, A. G., etal., Goodman and Gilman's THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, 7thEd., Macmillan Publishing Co., 1985.

The antibodies of this invention may be advantageously utilized incombination with other monoclonal or murine and chimeric antibodies,fragments and regions, or with lymphokines or hemopoietic growthfactors, etc., which serve to increase the number or activity ofeffector cells which interact with the antibodies.

XII. Transgenic PCA3 Non-Human Animals Methods of Generating TransgenicNon-Human Animals

The non-human animals of the invention comprise any animal having atransgenic interruption or alteration of the endogenous gene(s)(knock-out animals) and/or into the genome of which has been introducedone or more transgenes that direct the expression of human PCA3. Alsopreferred are the introduction of antisense PCA3 nucleic acids.

Such non-human animals include vertebrates such as rodents, non-humanprimates, sheep, dog, cow, amphibians, reptiles, etc. Preferrednon-human animals are selected from non-human mammalian species ofanimals, most preferably, animals from the rodent family including ratsand mice, most preferably mice.

The transgenic animals of the invention are animals into which has beenintroduced by nonnatural means (i.e., by human manipulation), one ormore genes that do not occur naturally in the animal, e.g., foreigngenes, genetically engineered endogenous genes, etc. The nonnaturallyintroduced genes, known as transgenes, may be from the same or adifferent species as the animal but not naturally found in the animal inthe configuration and/or at the chromosomal locus conferred by thetransgene. Transgenes may comprise foreign DNA sequences, i.e.,sequences not normally found in the genome of the host animal.Alternatively or additionally, transgenes may comprise endogenous DNAsequences that are abnormal in that they have been rearranged or mutatedin vitro in order to alter the normal in vivo pattern of expression ofthe gene, or to alter or eliminate the biological activity of anendogenous gene product encoded by the gene. (Watson, J. D., et al., inRecombinant DNA, 2d Ed., W.H. Freeman & Co., New York (1992), pages255-272; Gordon, J. W., Intl. Rev. Cytol. 115:171-229 (1989); Jaenisch,R., Science 240:1468-1474 (1989); Rossant, J., Neuron 2:323-334 (1990)).

The transgenic non-human animals of the invention are produced byintroducing transgenes into the germline of the non-human animal.Embryonic target cells at various developmental stages are used tointroduce the transgenes of the invention. Different methods are useddepending on the stage of development of the embryonic target cell(s).

1. Microinjection of zygotes is the preferred method for incorporatingtransgenes into animal genomes in the course of practicing theinvention. A zygote, a fertilized ovum that has not undergone pronucleifusion or subsequent cell division, is the preferred target cell formicroinjection of transgenic DNA sequences. The murine male pronucleusreaches a size of approximately 20 micrometers in diameter, a featurewhich allows for the reproducible injection of 1-2 picoliters of asolution containing transgenic DNA sequences. The use of a zygote forintroduction of transgenes has the advantage that, in most cases, theinjected transgenic DNA sequences will be incorporated into the hostanimal's genome before the first cell division (Brinster, et al., Proc.Natl. Acad. Sci. (USA) 82:4438-4442 (1985)). As a consequence, all cellsof the resultant transgenic animals (founder animals) stably carry anincorporated transgene at a particular genetic locus, referred to as atransgenic allele. The transgenic allele demonstrates Mendelianinheritance: half of the offspring resulting from the cross of atransgenic animal with a non-transgenic animal will inherit thetransgenic allele, in accordance with Mendel's rules of randomassortment.

2. Viral integration can also be used to introduce the transgenes of theinvention into an animal. The developing embryos are cultured in vitroto the developmental stage known as a blastocyst. At this time, theblastomeres may be infected with appropriate retroviruses (Jaenich, R.,Proc. Natl. Sci. (USA) 73:1260-1264 (1976)). Infection of theblastomeres is enhanced by enzymatic removal of the zona pellucida(Hogan, et al., in Manipulating the Mouse Embryo, Cold Spring HarborPress, Cold Spring Harbor, N.Y. (1986)). Transgenes are introduced viaviral vectors which are typically replication-defective but which remaincompetent for integration of viral-associated DNA sequences, includingtransgenic DNA sequences linked to such viral sequences, into the hostanimal's genome (Jahner, et al., Proc. Natl. Acad. Sci. (USA)82:6927-6931 (1985); Van der Putten, et al., Proc. Natl. Acad. Sci.(USA) 82:6148-6152 (1985)). Transfection is easily and efficientlyobtained by culture of blastomeres on a mono-layer of cells producingthe transgene-containing viral vector (Van der Putten, et al., Proc.Natl. Acad. Sci. (USA) 82:6148-6152 (1985); Stewart, et al., EMBOJournal 6:383-388 (1987)). Alternatively, infection may be performed ata later stage, such as a blastocoele (Jahner, D., et al., Nature298:623-628 (1982)). In any event, most transgenic founder animalsproduced by viral integration will be mosaics for the transgenic allele;that is, the transgene is incorporated into only a subset of all thecells that form the transgenic founder animal. Moreover, multiple viralintegration events may occur in a single founder animal, generatingmultiple transgenic alleles which will segregate in future generationsof offspring. Introduction of transgenes into germline cells by thismethod is possible but probably occurs at a low frequency (Jahner, D.,et al., Nature 298:623-628 (1982)). However, once a transgene has beenintroduced into germline cells by this method, offspring may be producedin which the transgenic allele is present in all of the animal's cells,i.e., in both somatic and germline cells.

3. Embryonic stem (ES) cells can also serve as target cells forintroduction of the transgenes of the invention into animals. ES cellsare obtained from pre-implantation embryos that are cultured in vitro(Evans, M. J., et al., Nature 292:154-156 (1981); Bradley, M. O., etal., Nature 309:255-258 (1984); Gossler, et al., Proc. Natl. Acad. Sci.(USA) 83:9065-9069 (1986); Robertson et al., Nature 322:445-448 (1986);Robertson, E. J., in Teratocarcinomas and Embryonic Stem Cells: APractical Approach, Robertson, E. J., ed., IRL Press, Oxford (1987),pages 71-112). ES cells, which are commercially available (from, e.g.,Genome Systems, Inc., St. Louis, Mo.), can be transformed with one ormore transgenes by established methods (Lovell-Badge, R. H., inTeratocarcinomas and Embryonic Stem Cells: A Practical Approach,Robertson, E. J., ed., IRL Press, Oxford (1987), pages 153-182).Transformed ES cells can be combined with an animal blastocyst,whereafter the ES cells colonize the embryo and contribute to thegermline of the resulting animal, which is a chimera (composed of cellsderived from two or more animals) (Jaenisch, R., Science 240:1468-1474(1988); Bradley, A., in Teratocarcinomas and Embryonic Stem Cells: APractical Approach, Robertson, E. J., ed., IRL Press, Oxford (1987),pages 113-151). Again, once a transgene has been introduced intogermline cells by this method, offspring may be produced in which thetransgenic allele is present in all of the animal's cells, i.e., in bothsomatic and germline cells.

However it occurs, the initial introduction of a transgene is aLamarckian (non-Mendelian) event. However, the transgenes of theinvention may be stably integrated into germ line cells and transmittedto offspring of the transgenic animal as Mendelian loci. Othertransgenic techniques result in mosaic transgenic animals, in which somecells carry the transgenes and other cells do not. In mosaic transgenicanimals in which germ line cells do not carry the transgenes,transmission of the transgenes to offspring does not occur.Nevertheless, mosaic transgenic animals are capable of demonstratingphenotypes associated with the transgenes.

Transgenes may be introduced into non-human animals in order to provideanimal models for human diseases. Transgenes that result in such animalmodels include, e.g., transgenes that encode mutant gene productsassociated with an inborn error of metabolism in a human genetic diseaseand transgenes that encode a human factor required to confersusceptibility to a human pathogen (i.e., a bacterium, virus, or otherpathogenic microorganism) (Leder et al., U.S. Pat. No. 5,175,383 (Dec.29, 1992); Kindt et al., U.S. Pat. No. 5,183,949 (Feb. 2, 1993); Smallet al., Cell 46:13-18 (1986); Hooper et al., Nature 326:292-295 (1987);Stacey et al., Nature 332:131-136 (1988); Windle et al., Nature343:665-669 (1990); Katz et al., Cell 74:1089-1100 (1993)).Transgenically introduced mutations comprise null (“knock-out”) allelesin which a DNA sequence encoding a selectable and/or detectable markeris substituted for a genetic sequence normally endogenous to a non-humananimal. Resultant transgenic non-human animals that are predisposed to adisease, or in which the transgene causes a disease, may be used toidentify compositions that induce the disease and to evaluate thepathogenic potential of compositions known or suspected to induce thedisease (Berns, A. J. M., U.S. Pat. No. 5,174,986 (Dec. 29, 1992)), orto evaluate compositions which may be used to treat the disease orameliorate the symptoms thereof (Scott et al., WO 94/12627 (1994)).

Offspring that have inherited the transgenes of the invention aredistinguished from littermates that have not inherited transgenes byanalysis of genetic material from the offspring for the presence ofbiomolecules that comprise unique sequences corresponding to sequencesof, or encoded by, the transgenes of the invention. For example,biological fluids that contain polypeptides uniquely encoded by theselectable marker of the transgenes of the invention may beimmunoassayed for the presence of the polypeptides. A more simple andreliable means of identifying transgenic offspring comprises obtaining atissue sample from an extremity of an animal, e.g., a tail, andanalyzing the sample for the presence of nucleic acid sequencescorresponding to the DNA sequence of a unique portion or portions of thetransgenes of the invention, such as the selectable marker thereof. Thepresence of such nucleic acid sequences may be determined by, e.g.,hybridization (“Southern”) analysis with DNA sequences corresponding tounique portions of the transgene, analysis of the products of PCRreactions using DNA sequences in a sample as substrates andoligonucleotides derived from the transgene's DNA sequence, etc.

The present invention is described in further detail in the followingnon-limiting examples.

Example 1 Isolation and Characterization of PCA3 cDNA and Genomic DNA

In order to identify new markers for prostate cancer, a differentialdisplay analysis (Liang et al., Science 257: 967-971 (1992)) was used toidentify genes overexpressed in prostatic carcinomas in comparison tonormal prostate; total RNA from normal, benign hyperplastic andmalignant prostatic tissue from the same patients was extracted. Usingtwenty different combinations of primers (four anchored primers, fivearbitrary primers), eleven apparently differentially expressed mRNAswere identified (i.e., consistently overexpressed in all carcinomasstudied and not expressed in normal or BPH tissue). The complementaryDNA (cDNA) fragments were used as probes for Northern blot analysis toconfirm the consistent overexpression in the prostatic tumors used forthe differential display. One of the probes (named DD3, a 486 bp cDNA)detected two major transcripts (2.3 and 4.0 kb) that are highlyoverexpressed in 47 of 50 human prostatic tumors studied, whereas no (orvery low levels of) expression of these transcripts was found in normalor BPH tissue from the same patients.

To obtain a full length cDNA clone, a cDNA library was constructed usingmRNA isolated from human primary prostatic tumor tissue. 250 positiveDD3 related clones were obtained from screening this library. 80 cloneswere purified and the nucleotide sequence of these clones was determinedby automated sequence analysis.

A genomic library constructed of human placenta genomic DNA cloned inλFIX2 was screened using DD3 as a probe. Four different clones wereobtained, two of them located towards the 5′ end of the gene (λFIX-ME3and -ME4) and two clones located towards the 3′ end of the gene(λFIX-ME1 and -ME2). The 5′ end of λFIX-ME4 was subcloned and used as aprobe to screen the genomic library. Three new, unique clones wereisolated (λFIX-1H1, IH2, and IH6).

From the 80 analyzed cDNA clones, at least four different transcriptswere shown to be present due to alternative splicing or alternativepolyadenylation. Sequence analysis of the genomic clones as compared tothe cDNA clones revealed the genomic structure of the PCA3 gene. Threeintrons and 4 exons are present. The first intron is approximately 20 kbin length.

The first cDNA species is found in approximately 5% of the cDNA clonesand contains exons 1, 2, 3, 4a and 4b (poly-adenylation after 4b ispreceded by a real consensus poly-A-addition signal) (FIG. 1).

The second cDNA species, found in approximately 15% of the cDNA cloned,contains exons 1, 3, 4a, 4b and 4c, arises by alternative splicing ofthe second exon (not present in this cDNA) and terminates at a different(real consensus) poly-A-addition signal (FIG. 1).

The third cDNA species contains exons 1, 3, 4a, and 4b and is the mostcommon one found (approximately 65% of 80 clones) (FIG. 1). This cDNA ismost likely responsible for the most prominent transcript seen byNorthern blot analysis (2 kb).

The fourth cDNA species detected contains exons 1, 3, and 4arepresenting about 15% of clones, and terminates after 4a, which is theoriginal DD3 clone stop site (FIG. 1). The poly-A-addition signalpresent here is close to the consensus sequence.

PCA3 is a gene wherein significant alternative splicing (as well asalternative poly-adenylation) occurs, as evidenced by the differentlysized transcripts observed on Northern blots and the different types ofclones identified. As mentioned previously, other splicing variants canbe identified, as virtually every combination of exons is possible. Forinstance, a cDNA clone having exons 2, 3, 4a, 4b, and 4c has recentlybeen identified. Indeed, it appears that clones representing virtuallyall possible exon combinations have been isolated.

One such splicing variant was identified by sequencing a clone namedλDD3.6. λDD3.6 is a λgt11 clone identified and isolated upon screeningof a cDNA library made from prostate RNA of a 25 year old male (obtainedfrom Clonetech) with a PCA3 probe. λDD3.6 contains exon 3, 4a, 4b, 4c,and 4d. However, this cDNA clone also contains intron sequences (part ofintron 2, as well as intron 3).

A comparison of the two deposited clones PMB9 and λDD3.6 is shown inFIG. 3.

Different combinations of exons were examined by computer analysis toidentify open reading frames (ORFs) and to predict the protein encodingregion. The longest ORF was also the most highly likely protein encodingregion. The longest ORF of 153 nucleotides encodes a small peptide of 51amino acids, PCA3. PCA3 is encoded by part of exon 3 and 4a. The smallsize of the protein suggests that the protein most likely functions as amessenger molecule and has the potential to be secreted from the cells.The nucleotide sequence of exons 1-4-a-d and the amino acid sequence ofPCA3 are shown in FIG. 2 and FIG. 5 (SEQ ID NO:1 and 6 and 2 and 7,respectively).

It will be recognized by the person of ordinary skill, that a cDNA clonecomprising the nucleic acid sequence presented in SEQ ID NO:6 and shownin FIG. 5 can be obtained as previously described by isolating andcharacterizing PCA3 cDNA clones. For example, and as commonly known inthe art, probes which are specific to at least one of the 5′ end, exon1, 2, 3, 4a, 4b, 4c and 4d can be further used to increase theprobability of having a full-length PCA3 cDNA clone. 96-well plates, forexample, can be used to screen a large number of PCA3 positive cDNAclones, using the probes mentioned above. Of course, PCA3 positiveclones can also be sequenced, as commonly known and as described herein,until a desired cDNA clone is obtained.

In addition it is also possible to obtain a cDNA clone comprising thesequence shown in SEQ ID NO:6 and shown in FIG. 5, using PCA3 specificprimers and an amplifying method such as PCR. For example, PCRtechnology with primers specific for the ultimate 5′ and 3′ end of thePCA3 cDNA, could be used to amplify a desired product (almost 4 kb) fromRNA, isolated for example from prostatic tumors, and clone the PCRproducts. However, since PCR amplification may introduce mistakes, asequencing of the complete cDNA would most likely be required.

As well known to the person of ordinary skill, a cDNA clone comprisingthe sequence shown in SEQ ID NO:6 and shown in FIG. 5 can also beconstructed using the clones described herein (or newly isolated ones)and conventional genetic engineering methods.

For example, such a full length cDNA clone can be constructed using thedeposited clones pMB9 and λDD3.6. A non-limiting example of a strategyto construct such a cDNA clone comprising the nucleic acid sequence ofSEQ ID NO:6 and FIG. 5, is described below.

λDD3.6 phage DNA is digested to completion with NdeI, and theapproximately 2 kb NdeI fragment isolated from an agarose gel. Thisfragment contains part of PCA3 exon 4b, exons 4c+4d and about 50nucleotides of phage DNA. The ends of this 2 kb fragment are then filledin with Klenow-fragment DNA polymerase and dNTPs, the blunt-endedfragment are then ligated into the HincII/SmaI sites of Bluescript SK.The loss of the HindIII site of Bluescript by the HincII and SmaIdigestion is essential for further cloning steps in this particularstrategy (see below). It is to be noted that NdeI sites are also presentin phage λgt11, giving rise to several additional fragments, some ofwhich are close to 2 kb (i.e., a 1.8 kb and a 2.5 kb fragment).Nevertheless, it is straight forward to separate these different bandson an agarose gel. The correct orientation of insertion of theblunt-ended 2 kb NdeI fragment of IDD3.6 into Bluescript (termedconstruct PCA3-X) can be verified by a single SacI digestion, whichshould yield a ˜0.45 and ˜4.5 kb fragment by Ethidium-bromide stainingof agarose gels. Sequence analysis may be performed to confirm theidentity of the PCA3 insert.

The PCA3-X construct is then digested to completion with HindIII andBamHI and a 4.8 kb vector-insert isolated from an agarose gel. Thisresults in the removal of ˜0.2 kb of DNA from the insert. pMB9 can besimultaneously digested to completion with BamHI and HindIII and the 1.9kb insert (containing PCA3 exons 1, 2, 3, 4a and most of exon 4b)isolated from an agarose gel. The pMB9-derived insert is ligated intothe BamHI/HindIII site of the PCA3-X construct. The resulting construct,PCA3-Y contains the complete cDNA of PCA3, except for the first 22nucleotides of exon1 (see below and FIG. 4). These 22 nucleotides can beadded to the PCA3 cDNA by cutting the PCA3-Y construct and theoligo-(74)-mer (SEQ ID NO:8) to completion with BamHI and PstI andligating the oligomer in construct PCA3-Y, resulting in constructPCA3-Z. Nucleotide sequence analysis can be performed to verify that theoligo was properly ligated (i.e. to confirm that just one oligo wasligated and not a whole array of oligos). Of course, a sequencing of theresulting cDNA in PCA3-Z, can be performed to verify the integrity ofthe nucleic acid sequence.

Screening of a somatic cell hybrid panel revealed that the gene encodingPCA3 is located on human chromosome 9. Using a mixture of fourPCA3-related genomic clones as a probe to hybridize to metaphasechromosomes of human lymphocytes, PCA3 was mapped to 9q21-22 (See also,FIG. 1).

The conservation of PCA3 gene during evolution was studied by Southernblot analysis and revealed that a homolog of this gene is present inmonkey, cow, horse, sheep, goat and pig. The gene is also present in dogand cat. By comparison, the gene encoding PSA is only found in primates.

Example 2 Prostate Specific Expression of PCA3

Upon developing PCA3 specific primers, RT-PCR analysis was performedusing RNA from several normal human tissues. At 40 cycles of PCR, PCA3related products in normal prostate and BPH tissues were amplified. PCA3expression is very prostate specific since no PCA3 product could beamplified under these conditions in the following normal human tissues:artery, brain, breast, bladder, colon, duodenum, heart, liver, lung,ovary, pancreas, placenta, seminal vesicles, skeletal muscle, skin,spinal cord, spleen and testis. Also in the human prostate cancer celllines ALVA-31, DU145, JCA-1, PPC-1, PC3, and TSU-Pr1 no PCA3 related PCRproduct could be detected. In the cell line LNCaP a product can beobtained after 40 cycles of PCR (whereas under the same conditions aproduct can be obtained in prostatic tumors within 20 cycles). Thetechnology used to assess the prostate specific expression of PCA3 canbe adapted in a diagnostic test for prostate cancer. In addition, it canbe adapted to the identification of the prostatic origin of a metastase.

Furthermore, a semi-quantitative RT-PCR analysis to compare theexpression of PCA3 to that of PSA (prostate-specific antigen) and PSM(prostate-specific membrane antigen) and to establish if PCA3-RT-PCRanalysis can be used to distinguish malignant from benign prostaticspecimens was performed. After quantification of the RT-reaction, 10 ngof cDNA was used for the PCR reaction and as a control, beta-2microglobulin was also examined. PCA3 products found allowed a cleardistinction between benign and malignant specimens in 23 of 25 casesstudied whereas PSA and PSM could not make this distinction:approximately equal amounts of product were found in normal and tumorsamples. The expression of PSA and PCA3 was also compared by Northernblot analysis, which clearly shows the higher tumor-specificity of PCA3.At least a 20-fold overexpression of PCA3 in prostatic carcinomas ascompared to normal or BPH tissues is observed. This is distinctlydifferent from expression of PSM and PSA, both of which are decreased inmalignant versus benign tissues. Thus, PCA3 appears to be a good markerfor diagnostic of prostate cancer.

An ideal tumor marker for prostate cancer should not only be able topositively distinguish between benign and malignant tissues but also beable to predict clinical outcome (cure or progression) of patientsafflicted with this disease. Data has shown that indeed, the level ofexpression of PCA3 tends to be positively correlated with tumor grade.

RISH (and eventually immunohistochemistry) is used to establish whetheror not there is correlation between overexpression of PCA3, tumor grade,stage, and clinical outcome. For both the paraffin-embedded and frozenspecimens, long-term clinical follow-up is available. Usingcomputer-assisted image analysis, quantitation of PCA3 expression levelsas detected by RISH is performed and this is normalized to an externalreference (Tamimi et al., Cancer Res. 53: 5512-16 (1993); Tamimi et al.,B.J. Cancer (1996)). A multivariate regression analysis includingGleason: grade, pathological tumor stage, clinical tumor stage, PSAlevels and PCA3 expression will be used to establish whether PCA3 is anaccurate predictor of progression and has (additional) prognostic value.

Reverse transcriptase polymerase chain reaction (RT-PCR) assays havebeen developed to detect occult hematogenous micrometastatic cells thatmight otherwise have gone undetected by presently available stagingmodalities. Such RT-PCR assays have already been performed in patientswith prostate cancer and other malignancies. A highly sensitive (nested)RT-PCR assay (or other types of amplification assays including withoutbeing limited to NASBA, PCR, QB rep., SOA, TMA, and LCR (Winn-Deen, J.Clin., Liquid Assay 19: 21-26 (1996)) can be used to detect prostatecancer cells in the circulating blood of prostate: cancer patients toidentify patients at risk for having or developing metastases.Experiments will include appropriate controls (e.g. β-2-microglobulin)and will be performed in a semi-quantitative way (i.e., quantify thecDNA synthesis and use equal amounts of input for the PCR analysis).

The molecular staging studies will be performed in the larger context ofthe BIOMED II program (Markers for Prostate Cancer). In this extensivecollaborative study, PSA and PSM will be studied as well as otherpotentially interesting markers for prostate cancer. Blood samples arealready being collected from patients that are diagnosed with prostaticdisease in the participating institutions. An optimization of thecollecting and handling of blood samples from patients for the detectionof circulating tumor cells has been initiated. The use for example ofVacutainer™ CPT-tubes (BecktonDickinson) for blood collection andpurification of peripheral blood leukocytes in combination with aTrizol™ RNA-extraction procedure (guanidinium thiocyanate based)resulted in the preparation of RNA qualitatively and quantitativelysuitable for PCR analysis. The use of PCA3-specific primers, to amplifyPCA3 transcripts in RNA extracted from blood from prostate cancerpatients, revealed that the presence of prostate cancer cells in theblood circulation, of not only patients with proven metastases, but alsoof patients with assumed localized disease, could be detected. Moreextensive studies on a larger patient population and a correlation withclinical data and follow-up will be carried out to determine theprognostic value of PCA3 for the individual prostate cancer patient.

Nested RT-PCR analysis (or similar amplification methods) should proveinstrumental in determining whether there are any organs (not yettested) that express PCA3. For example, Cowper's gland (same embryonicorigin as the prostate) and also skene's gland (female “homologue” tothe prostate) will be tested for PCA3.

In one “normal” prostate tissue specimen that contained 10% of tumorcells, PCA3 expression was detected indicating the high sensitivity ofPCA3 as a tumor marker. In this manner, PCA3 expression was alsodetected in a few BPH samples that were subsequently found to containsmall areas of tumor cells. The level of expression of PCA3 in prostaticcancers shows a trend towards a positive correlation with tumor grade.These data are based on analysis of autoradiographs resulting fromNorthern blot hybridization.

The observation that PCA3 expression seems to increase with loss ofdifferentiation is different from what is reported for PSA, since PSAexpression levels decrease with loss of differentiation (Hakalahti etal., Int. J. Cancer 55:590-597 (1993)). There is at least 20-foldoverexpression of PCA3 in prostatic carcinomas in comparison to normalor BPH tissues. This is distinctly different from the expression of PSAwhich is reported to decrease in malignant versus benign tissues. PCA3expression was detected in 4 of 4 metastases studied.

Example 3 Identification of a Transcription Start Site of PCA3

In order to determine the transcription start site of PCA3 primerextension analysis, S1-nuclease mapping and 5′RACE (rapid amplificationof cDNA ends) assays were performed. The major transcription start sitewas found to be located within a range of 4 nucleotides (FIG. 4).

The results of these experiments further lengthen the size of the cDNAin a 5′ direction by a further 22 nt with respect to the cDNA sequenceof pMB9 (SEQ ID NO:1 and FIG. 2). This additional 5′ polynucleotidesequence is also shown in SEQ ID NO:6 and FIG. 5).

While the foregoing invention has been described in some detail forpurposes of clarity and understanding, it will be appreciated by oneskilled in the art from a reading of this disclosure that variouschanges in form and detail can be made without departing from the truescope of the invention and appended claims.

Although the present invention has been described hereinabove by way ofpreferred embodiments thereof, it can be modified, without departingfrom the spirit and nature of the subject invention as defined in theappended claims.

1. A method of determining whether a sample contains a PCA3 nucleicacid, comprising: a) contacting said sample with a nucleic acid molecule10 to 100 nucleotides in length comprising a sequence of at least 10consecutive nucleotides contained within SEQ ID NO:1, SEQ ID NO:3, SEQID NO:4, SEQ ID NO:6 or a sequence fully complementary thereto; and b)detecting binding of said nucleic acid molecule to the PCA3 nucleicacid, whereby it is determined that said sample contains the PCA3nucleic acid.
 2. The method of claim 1, wherein said sequence of atleast 10 consecutive nucleotides contained within SEQ ID NO:1, SEQ IDNO:3, SEQ ID NO:4, SEQ ID NO:6 or a sequence fully complementary theretois a sequence of at least 15 consecutive nucleotides contained withinSEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6 or a sequence fullycomplementary thereto.
 3. The method of claim 2, wherein saidoligonucleotide of 10 to 100 nucleotides in length is an oligonucleotide10 to 50 nucleotides in length.
 4. The method of claim 2, wherein saidoligonucleotide of 10 to 100 nucleotides in length is an oligonucleotide10 to 35 nucleotides in length.
 5. The method of claim 2, wherein saidoligonucleotide of 10 to 100 nucleotides in length is an oligonucleotideof 20 to 100 nucleotides in length.
 6. The method of claim 2, whereinsaid sequence of at least 15 consecutive nucleotides contained withinSEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:6 encodes a pluralityof consecutive amino acids of the predicted PCA3 polypeptide of SEQ IDNO:2.
 7. The method of claim 6, wherein said nucleic acid molecule of 10to 100 nucleotides in length is a nucleic acid molecule of 20 to 100nucleotides in length.
 8. The method of claim 2, wherein the detectingcomprises detecting in a nucleic acid hybridization procedure, andwherein said nucleic acid molecule comprises a detectable label.
 9. Themethod of claim 6, wherein the detecting comprises detecting in anucleic acid hybridization procedure, and wherein said nucleic acidmolecule comprises a detectable label.
 10. The method of claim 6,wherein said sequence of at least 15 consecutive nucleotides containedwithin SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:6 that encodessaid plurality of consecutive amino acids of the predicted PCA3polypeptide of SEQ ID NO:2 comprises nucleotides 381-400 of SEQ ID NO:1.11. The method of claim 6, wherein said sequence of at least 15consecutive nucleotides contained within SEQ ID NO:1, SEQ ID NO:3, SEQID NO:4 or SEQ ID NO:6 that encodes said plurality of consecutive aminoacids of the predicted PCA3 polypeptide of SEQ ID NO:2 comprisesnucleotides 381-410 of SEQ ID NO:1.
 12. The method of claim 6, whereinsaid sequence of at least 15 consecutive nucleotides contained withinSEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:6 that encodes saidplurality of consecutive amino acids of the predicted PCA3 polypeptideof SEQ ID NO:2 comprises nucleotides 401-420 of SEQ ID NO:1.
 13. Themethod of claim 6, wherein said sequence of at least 15 consecutivenucleotides contained within SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4 orSEQ ID NO:6 that encodes said plurality of consecutive amino acids ofthe predicted PCA3 polypeptide of SEQ ID NO:2 comprises nucleotides401-430 of SEQ ID NO:1.
 14. The method of claim 6, wherein said sequenceof at least 15 consecutive nucleotides contained within SEQ ID NO:1, SEQID NO:3, SEQ ID NO:4 or SEQ ID NO:6 that encodes said plurality ofconsecutive amino acids of the PCA3 predicted polypeptide of SEQ ID NO:2comprises nucleotides 427-446 of SEQ ID NO:1.
 15. The method of claim 6,wherein said sequence of at least 15 consecutive nucleotides containedwithin SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:6 that encodessaid plurality of consecutive amino acids of the predicted PCA3polypeptide of SEQ ID NO:2 comprises nucleotides 447-466 of SEQ ID NO:1.16. A method of determining whether a sample contains a PCA3 nucleicacid, comprising: a) contacting said sample with a nucleic acid molecule10 to 100 nucleotides in length comprising a sequence of at least 10consecutive nucleotides contained within SEQ ID NO:1, SEQ ID NO:3, SEQID NO:4, SEQ ID NO:6 or a sequence fully complementary thereto, b)detecting binding of said nucleic acid molecule to the PCA3 nucleicacid, whereby it is determined that said sample contains the PCA3nucleic acid, wherein said nucleic acid molecule does not specificallyhybridize to nucleotides 511-985 of SEQ ID NO:1, nucleotides 346-820 ofSEQ ID NO:3, nucleotides 346-820 of SEQ ID NO:4 or nucleotides 533-1007of SEQ ID NO:6 under stringent conditions of 0.2×SSC and 0.1% SDS at 68degrees C.
 17. The method of claim 16, wherein said sequence of at least10 consecutive nucleotides contained within SEQ ID NO:1, SEQ ID NO:3,SEQ ID NO:4, SEQ ID NO:6 or a sequence fully complementary thereto is asequence of at least 15 consecutive nucleotides contained within SEQ IDNO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6 or a sequence fullycomplementary thereto.
 18. The method of claim 17, wherein saidoligonucleotide of 10 to 100 nucleotides in length is an oligonucleotide10 to 50 nucleotides in length.
 19. The method of claim 17, wherein saidoligonucleotide of 10 to 100 nucleotides in length is an oligonucleotideof 10 to 35 nucleotides in length.
 20. The method of claim 17, whereinsaid oligonucleotide of 10 to 100 nucleotides in length is anoligonucleotide of 20 to 100 nucleotides in length.
 21. The method ofclaim 17, wherein said sequence of at least 15 consecutive nucleotidescontained within SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:6encodes a plurality of consecutive amino acids of the predicted PCA3polypeptide of SEQ ID NO:2.
 22. The method of claim 21, wherein saidnucleic acid molecule of 10 to 100 nucleotides in length is a nucleicacid molecule of 20 to 100 nucleotides in length.
 23. The method ofclaim 17, wherein the detecting comprises detecting in a nucleic acidhybridization procedure, and wherein said nucleic acid moleculecomprises a detectable label.
 24. The method of claim 21, wherein thedetecting comprises detecting in a nucleic acid hybridization procedure,and wherein said nucleic acid molecule comprises a detectable label. 25.The method of claim 21, wherein said sequence of at least 15 consecutivenucleotides contained within SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4 orSEQ ID NO:6 that encodes said plurality of consecutive amino acids ofthe predicted PCA3 polypeptide of SEQ ID NO:2 comprises nucleotides381-400 of SEQ ID NO:1.
 26. The method of claim 21, wherein saidsequence of at least 15 consecutive nucleotides contained within SEQ IDNO:1, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:6 that encodes saidplurality of consecutive amino acids of the predicted PCA3 polypeptideof SEQ ID NO:2 comprises nucleotides 381-410 of SEQ ID NO:1.
 27. Themethod of claim 21, wherein said sequence of at least 15 consecutivenucleotides contained within SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4 orSEQ ID NO:6 that encodes said plurality of consecutive amino acids ofthe predicted PCA3 polypeptide of SEQ ID NO:2 comprises nucleotides401-420 of SEQ ID NO:1.
 28. The method of claim 21, wherein saidsequence of at least 15 consecutive nucleotides contained within SEQ IDNO:1, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:6 that encodes saidplurality of consecutive amino acids of the predicted PCA3 polypeptideof SEQ ID NO:2 comprises nucleotides 401-430 of SEQ ID NO:1.
 29. Themethod of claim 21, wherein said sequence of at least 15 consecutivenucleotides contained within SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4 orSEQ ID NO:6 that encodes said plurality of consecutive amino acids ofthe PCA3 polypeptide of SEQ ID NO:2 comprises nucleotides 427-446 of SEQID NO:1.
 30. The method of claim 21, wherein said sequence of at least15 consecutive nucleotides contained within SEQ ID NO:1, SEQ ID NO:3,SEQ ID NO:4 or SEQ ID NO:6 that encodes said plurality of consecutiveamino acids of the predicted PCA3 polypeptide of SEQ ID NO:2 comprisesnucleotides 447-466 of SEQ ID NO:1.
 31. The method of claim 1, whereinsaid sequence of at least 10 consecutive nucleotides is contained withina PCA3 exon sequence selected from the group consisting of: a) PCA3 exon1, as set forth between nucleotides 1-98 of SEQ ID NO:1 or 1-120 of SEQID NO:6; b) PCA3 exon 2, as set forth between nucleotides 99-263 of SEQID NO:1 or 121-285 of SEQ ID NO:6; c) PCA3 exon 3, as set forth betweennucleotides 264-446 of SEQ ID NO:1 or 286-468 of SEQ ID NO:6; d) PCA3exon 4a, as set forth between nucleotides 447-985 of SEQ ID NO:1 or469-1007 of SEQ ID NO:6; e) PCA3 exon 4b, as set forth betweennucleotides 986-2037 of SEQ ID NO:1 or 1008-2066 of SEQ ID NO:6; f) PCA3exon 4c, as set forth between nucleotides 2067-2622 of SEQ ID NO:6; g)PCA3 exon 4d, as set forth between nucleotides 2623-3582 of SEQ ID NO:6;and h) a combination of said PCA3 exon sequences of a) to g).
 32. Themethod of claim 1, wherein said nucleic acid molecule is or iscomplementary to the polynucleotide sequence encoding the predicted PCA3open reading frame (ORF) set forth from nucleotides 379 to 531 of SEQ IDNO:1 or from nucleotides 401 to 553 of SEQ ID NO:6.